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 ABSTRACT 
 
 
Dietary Folate, Other B-vitamins and Incident Alzheimer’s Disease:  
the Cache County Memory, Health, and Aging Study 
 
 
by 
 
Chailyn Nelson, Master of Science 
Utah State University, 2008 
 
 
Major Professor: Dr. Heidi J. Wengreen 
Department: Nutrition and Food Sciences 
 
 
This study involves data from the Cache County Study, which began in 1994 with 
joined efforts by Duke University, Utah State University, and Johns Hopkins University.  
It consisted of 5,092 participants from Cache County, Utah, located in the northern part 
of the state.  Characteristics of the population include high participation rates (~ 90%), a 
majority of participants are members of The Church of Jesus Christ of Latter-day Saints, 
longer life expectancy than the general US population, a greater than 80% rate of at least 
a high school education, and low rates of migration. 
Subjects’ cognitive status was screened using the Modified Mini-Mental State 
Examination or rated by knowledgeable informants using an Informant Questionnaire for 
Cognitive Decline.  Low scoring subjects were examined using the Dementia 
Questionnaire, an inventory of cognitive symptoms, functional impairments, and medical 
conditions relevant to dementia.  The clinical data were reviewed by a geropsychiatrist 
and neuropsychologist.  Those suspected of dementia underwent further testing and final 
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dementia diagnoses were decided by a consensus conference of experts.  Clinical 
assessment at the baseline interview identified 368 individuals out of the original 5,092 
subjects as having dementia.  These individuals were removed from the present analysis.  
Prevalent cases of dementia were excluded in our analyses of risk associated with 
incident AD. 
Dietary data were collected using a food frequency questionnaire at baseline in 
1995.  A list of 142 foods was provided and participants noted frequency they consume 
the food or food group.  To calculate intake of a specific nutrient, the nutrient content of 
each food is multiplied by the frequency of consumption for each food.  This number is 
summed over all food items.  
Cox Proportional hazards modeling was used to assess risk of incident AD in 
relationship to folate and B-vitamin intake over eleven subsequent years of data 
collection.  Cox modeling assists in analysis of censored cases (drop-outs and deaths).  
No relationship was found between folate from food, supplement, or combined sources 
with dementia or with AD.  Similar results were observed for B-12 and B-6.      
 (129 pages) 
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CHAPTER 1 
 
BACKGROUND AND INTRODUCTION 
 
ABSTRACT 
Alzheimer’s disease (AD) is a neurodegenerative disease with devastating and 
debilitating consequences (1).  Diet is among several modifiable factors that likely play a 
role in an individual’s risk of developing AD (2, 3).  B-vitamins such as folate, vitamin 
B-12, and vitamin B-6 are particularly interesting due to their role in one carbon transfers 
or methylation reactions including homocysteine metabolism (4).  Deficiencies of B-
vitamins are known to cause elevated levels of homocysteine and 
hyperhomocysteinaemia has been observed at high rates among individuals with 
dementia (4).  Elderly men and women have increased risk for B-vitamin deficiency due 
to malabsorption of these nutrients caused by gastritis, interaction with medications, and 
conditions like pernicious anemia (5, 6).  Since the mandate for folate fortification of the 
US food supply in 1998, folate’s potential to mask a B-12 deficiency has become more of 
a concern for this population as prolonged vitamin B-12 deficiency can result in 
irreversible neuronal damage (6, 7).  The results of previous studies examining B-
vitamins and cognitive function are inconclusive.  The objective of this thesis is to 
examine associations between B-vitamins and incidence of Alzheimer’s disease in a 
cohort of aging men and women of the Cache County Memory Study. 
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BACKGROUND 
 
Alzheimer’s disease defined 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that  results 
in shrinkage of the frontal and temporal lobes of the brain effecting emotions, learning 
and memory functions (8).  AD is the most common cause of dementia and accounts for 
approximately 70% of all dementia cases (9).  Some critical components used to 
diagnosed AD, though the criteria vary, are a decline in cognition including memory loss, 
impairment in performing activities of daily living and a progressive pattern of decline 
and impairment (10).   
 
Cost of Alzheimer’s disease 
Alzheimer’s disease significantly reduces quality of life in affected individuals 
and their caretakers.  In 2004, it was reported that Alzheimer’s disease (AD) affected 
nearly 2% of people living in industrialized countries (8).  With the aging of the Western 
populations, it has been reported that the incidence of the disease is expected to more 
than double by 2050 (8, 11).  It is suspected that this is mostly due to the aging of the US 
population. As the baby boomers (born in 1946-1964) age there will be more people alive 
at the high-risk ages (11) 
AD increased the cost of health care by an estimated $80 to $100 billion dollars in 
2003 (3).  It ranks third behind heart disease and cancer for most costly disease in the US 
(3).  In 1991, Medicaid spent $5.7 billion dollars in care for AD patients and in 1996, the 
estimated cost for caring for a patient with AD was about $18,000-$36,000 per year 
depending upon severity (12, 13).  Though researchers have learned much about the 
  
3 
 
disease in the last few years, there are still many uncertainties surrounding the risk 
factors, causes, and effective treatment of AD (3).  
Delaying or slowing the progression of AD would lead to substantial savings in 
healthcare and extended periods of high quality life.  In 1998, a one month delay in need 
for institutionalized care for dementia and AD patients would yield savings of $1,863 in 
formal services per individual per year and collectively $1.12 billion annually (13).  It is 
obvious that AD is one of the most costly and fastest growing public health problems of 
today, and that delaying onset could have significant financial benefits.  More 
importantly delaying onset or slowing progression may help elders live independently for 
a longer period of time and decrease caregiver burdens. 
 
Etiology and pathology 
 The pathology behind neuron cell death and cognitive decline is not completely 
understood.  There are several theories and possible mechanisms that likely contribute to 
normal synapse failure and neuron death.  “Plaques” made of amyloid β-peptide 
accumulate between nerve cells and “tangles” made of fibrillar substances made of the 
tau protein form within nerve cells are thought to increase oxidative stress that damages 
DNA, proteins, and lipids of neurons in the brain (8).  When phosphorylated fibrillary 
proteins accumulate; these are known as the “tangles.”  Moderate or mild build-up of 
tangles is associated with normal aging processes, but increased numbers may be a cause 
of neuron death associated with AD (10).   
Whereas tangles are intracellular lesions, senile plaques form extracellularly.  
Amyloid material derived from a precursor protein called amyloid-beta precursor protein 
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(APP), can be deposited on neurons causing dystrophic neurites (1).  The normal form 
of APP has many functions; one role is thought to be in neural growth and repair (14). 
Dystrophic neurites exhibit “distorted” neuron processes or abnormal synapse processes 
(10).  The proportion of individuals with plaques increases with age and by the 80th 
decade of life, 75% of the population has at least some degree of plaque concentration, 
although a high degree of variation exists among individuals, even among the oldest old.  
Plaques begin as non-aggregated and harmless deposits but in some individuals a 
transformation occurs and innocuous plaques become dystrophic plaques associated with 
AD.  The exact cause of this transformation is unknown, some theorize the enzyme 
butyrycholinesterase is involved (10).  Though older individuals are more likely to have 
plaques, the number of plaques is relatively low in elderly with normal cognition (10).  
The amyloid cascade begins with antecedent events such as genetics, environment 
and lifestyle contributing to amyloid production.   Enzymes called secretases including 
the alpha, beta, and gamma type involved in splicing protein segments that form APP, 
play a large role in whether a deposition of amyloid occurs in excess or not.  This brings 
up interesting questions in the field of genetics; those with genotypes for certain types of 
secretases may have more or less predisposition for AD (8).  The dysfunction of neurons 
is not the only theorized cause of cognitive decline.  Amyloid buildup is thought to cause 
inflammation, oxidative stress and to impair neurogenesis (8).   
The order in which these events happen (amyloid deposition, inflammation, 
oxidative damage, etc.) and how they contribute to the etiology of the disease is often 
debated.  Some believe that plaques cause inflammation and oxidative damage others 
believe the oxidative damage occurs prior to plaque formation.  The latter theory is 
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derived from the hypothesis that oxidative stress, through a series of enzymatic steps, 
may cause alterations in the processing of APP or tau leading to plaques and tangles.  In 
an article discussing mitochondria and neurodegenerative diseases, it is said that 
mutations in mitochondria DNA contribute to diseases like AD.   As people age they 
accumulate more mutations which may lead to increased ROS production (15).   
 
Contributing factors 
Alzheimer’s disease has been found to be associated with a variety of 
environmental and inherited factors.  Non-modifiable factors include age, gender and 
apoE genotype.  Modifiable factors include diet, physical activity, education, etc.  
Though AD is strongly associated with age and genetic risk, it is well accepted that many 
additional factors such as diet and exercise have a large impact on risk for and 
progression of the disease (3). 
 
Prevention and treatment 
Pharmaceuticals targeting different areas of the neurodegenerative cascade have 
been developed and tested.  For example, blockers of neurotoxic substances and drugs 
that chelate copper and iron have been tested.   Non-steroidal anti-inflammatory agents 
and substances that may cue the immune system to remove harmful matter from the brain 
are also being explored (8).  Common pharmaceuticals like cholinesterase have been 
found to provide modest effects, but are often accompanied with severe gastrointestinal 
side effects (16).  Due to the variability in effectiveness and relatively mild improvements 
made by pharmaceutical agents, more preventive measures need to be defined, including 
diet modifications which might reduce earlier and faster cognitive decline.   
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The study of diet and AD has boasted a lot of attention the last few years; 
interestingly, this coincides with the projected increase in prevalence of AD.   The New 
Mexico Aging Process Study is a longitudinal study which began in 1979.  A paper 
reporting on nutrition status and cognition was done on the cohort using data from a 6-
year reassessment.  The cohort included 137 elderly who were well educated, healthy, 
financially secure, and generally health conscious.  Three day diet records, biochemical, 
anthropometric and clinical measurements were taken.  The results included a modest 
relationship between nutrition status and cognitive decline.   Nutrition status was based 
on dietary intake and correlated biochemical markers of vitamin c, thiamine, riboflavin, 
niacin, folate, vitamin B-6, vitamin B-12, protein, and iron.  The positive associations 
were noted for protein, folate, niacin, ascorbate, vitamins B-6 and B-12, thiamine, and 
riboflavin (17).  
 
FIGURE 1.1 One-Carbon Metabolism (Adapted from Lim, 2005) (18) 
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One-carbon metabolism and B-vitamins 
The figure above (Figure 1.1) shows the interrelationsthips between B-vitamins 
and homocysteine  in methylation reactions including the formation of methionine for S-
adenosyl-methionine (the methyl donor for essential reactions in the brain) (9).  It is clear 
that for these reactions to function properly folate must be present.  In one-carbon 
metabolism which is the transfer of methyl groups from donors to acceptors, folate as a 
part of 5-methyl-tetrahydrofolate assists in the methylation of homocysteine to 
methionine along with the enzyme methionine synthase and vitamin B-12.  This step of 
methionine production from homocysteine is very important as it provides a substrate for 
SAM (9).     
 B-12 is a required cofactor for the remethylation of homocysteine to methionine 
(9).  A deficiency of SAM may also occur with deficiency of B-12 even in the presence 
of adequate folate.  The conversion of 5,10 methylene-THF to 5-methyl-THF, the methyl 
donor for homocysteine, requires the enzyme methyltetrahydrofolate reductase.  This 
reaction is irreversible; therefore B-12 deficiency leading to 5-methyl-THF excess is 
known as the methyl-folate trap.  This trapping of folate as 5-methyl-THF also results in 
a lack of folate precursors needed for DNA synthesis and red blood cell maturation (7).   
Vitamin B-6’s role in one-carbon metabolism is as a cofactor for that metabolize 
homocysteine through an alternate pathway and as a cofactor for serine transhydroxy-
methylase between tetrahydrofolate (THF) and 5, 10 methylene-THF.  Homocysteine 
may be converted into several different products including: 1) methionine, 2) 
cystathionine, and 3) homocysteine sulfinic acid.  Vitamin B-6 is involved in the 
conversion of homocysteine to both cystathionine and homocysteine sulfinic acid (9).  
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Mechanistically deficiency of folate, vitamin B-12 and vitamin B-6 independent of each 
other may result in excess homocysteine, deficiency in SAM, and a lack of folate 
precursors involved in DNA synthesis and red blood cell maturation.  The status of one 
may affect the importance of other B-vitamins.  For example, B-6 may become very 
important in the presence of other B-vitamin deficiencies.  In a rat model, B-6 deficient 
rats were seen to have adverse increases in homocysteine compared to the folate deficient 
rats (19).  In addition, adding methionine resulted in increased SAM in folate deficient 
rats and signaled further homocysteine catabolism, indicating that B-6 may be critical for 
homocysteine metabolism in the presence of folate deficiency.  In the B-6 deficient rats, 
an increase in SAM prevented homocysteine remethylation therefore increases in plasma 
homocysteine levels (19). 
In addition to folate, vitamin B-12, vitamin B-6, there are other nutrients 
including riboflavin, betaine, and zinc that are important for one-carbon metabolism.  A 
few publications note riboflavin’s involvement related to its role in genetic predisposition 
to low folate status and/or high total homocysteine (tHcy) levels (20).  Riboflavin is a 
cofactor to methyltetrahydrofolate reductase (Figure 1.1), an enzyme required for 
conversion of 5,10 methylene-THF to 5-methyl-THF.  Little research examining 
interactions between riboflavin, folate, B-12, B-6 and cognition is available.  Betaine, a 
metabolite of choline, has also been mentioned in this area due to its involvement in an 
alternate methlyation pathway of homocysteine; this occurs mainly in the liver and little 
research has been done involving betaine (4).  Niacin and thiamine deficiencies are now 
rare in the US, but also have neurologic effects during deficiency.  Pellagra, caused by 
niacin deficiency is known to cause dementia, diarrhea, and dermatitis.  Wernicke-
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Korsakoff syndrome, is the result of thiamine deficiency often seen in alcoholics, and is 
associated with memory loss and hallucinations.  Thiamine deficiency results in 
macrocytic anemia but no neurologic syndromes have been identified (21).  Niacin and 
thiamine have received less attention in major cognitive studies.  
 
One-carbon metabolism and AD 
Dysfunction of one-carbon metabolism may contribute to cerebral atrophy and 
neuronal cell death (22).  Disturbed one-carbon metabolism could be linked in several 
ways to AD.  Although details regarding these proposed mechanisms are unclear, 
prolonged folate and B-12 deficiency may lead to hyperhomocysteinaemia.  Elevated 
levels are generally considered to increase oxidative stress leading to damaged neurons 
(10, 23).  In several studies elevated homocysteine has been found to be associated with 
increased risk for AD or to faster cognitive decline (4).   
Another potential mechanism associating one-carbon metabolism and AD exists 
via a deficiency of SAM.  SAM deficiency may also result from folate or B-12 deficiency 
or both, preventing homocysteine from being methylated to methionine, the precursor for 
SAM (Figure 1.1).  Inadequate SAM alters normal methylation of nucleoproteins, 
proteins, membrane phospholipids, and neurotransmitters essential for normal brain 
function (4, 9, 24, 25).  In addition to this, SAM is converted to S-adenosylhomocysteine 
(SAH) which is hydrolyzed to homocysteine.  When homocysteine metabolism is halted 
SAH surplus is favored, and SAH  may inhibit several enzymes of SAM metabolism 
(26).   Like homocysteine and B-vitamin levels in AD patients, SAM has also been 
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observed at low serum levels in patients with AD and postmortem in brain tissue of 
AD patients (24). 
In addition, through a series of reactions beginning with metabolites in one-
carbon metabolism glutathione is produced.  Glutathione is a major contributor to 
reduction of oxidative stress in the brain, and reduced glutathione stores have been 
observed in AD patients.  Some of the reactions leading to production of glutathione 
require vitamin B-6 and SAM (23).  Finally, specific folate metabolites are required for 
pyrimidine and purine synthesis (4).  Deficiencies of these metabolites can be caused by 
methyl-folate trap (previously discussed) and may cause mutations or breaks in DNA.  
Damaged DNA has been implicated in cancers and neurologic defects (27).   
 
Folate’s roles 
Folate acts as a cofactor for several enzymes that aid in prevention of anemia, 
cardiovascular disease, thromboembolitic processes, neural tube defects and other 
congenital defects, adverse pregnancy outcomes, neuropsychiatric disorders, and cancer 
(28).  Folic acid is the fully oxidized monoglutamyl form of the vitamin and is used 
commercially in supplements and in fortified foods (28).  Though folate has received the 
most attention of the B-vitamins in relation to cognition, other B-vitamins such as 
vitamins B-12 and B-6 and their role in cognitive health should not be discounted.  If 
folate deficiency was the only B-vitamin deficiency involved, a decline or slowing in the 
rates of AD with folate fortification would have been expected.  No evidence exists that a 
decrease in AD rates has occurred, although this may be related to poor surveillance of 
AD rates.    
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Vitamin B-12, neuropathy and macrocytic anemia 
 Vitamin B-12 deficiency is often accompanied by hematologic, neurologic 
(paresthesias, peripheral neuropathy, demyelination), psychiatric (irritability, mild 
memory impairment, dementia, depression, psychosis), and possible cardiovascular 
symptoms (29).  Deficiency of B-12 has been found to be related to neurologic damage 
due to altered methylation reactions (30).  Vitamin B-12 is also required for the 
conversion of methylmalonic acid to succinyl-CoA.  Deficiency in B-12 leads to elevated 
methylmalonic acid (29).  Some studies have proposed methylmalonic aciduria may 
damage mitochondria involved in mitochondrial oxidative phosphorylation and this 
appears to effect brain tissue.   It may also inhibit kinase reactions in the brain, by 
inhibiting mitochondria creatine kinase in the cerebral cortex (31).  A deficiency of either 
folate or vitamin B-12 also leads to macrocytic anemia but isolated B-12 deficiency 
results in neurological symptoms and can occur in the absence of anemia, the primary 
indicator of deficiency (5).   
 
Prevalence of B-vitamin deficiencies 
A high prevalence of folate and B-12 deficiency is observed among older people 
in the US.  Vitamin B-12 deficiency rates were found to increase with age in three studies 
of elderly living in the United Kingdom and on average 1/20 age 65-74 were deficient 
and 1/10 age 75+ were deficient (5).  The review of studies done on UK elderly also 
found folate deficiency to increase with age but only 10% of people with low B-12 also 
had low folate levels. The blood samples were drawn during the later half of the 1990’s 
from all three studies (5).  Kim (28) states vitamin B-12 deficiency may be the larger 
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problem and may affect up to 10-15% of the population over 60 years of age.  
Deficiency of B-12 is commonly associated with hypochlorhydria, pernicious anemia, 
and atrophic gastritis (5).  
 Vitamin B-12 is absorbed in the small intestine.  Hydrochloric acid (HCl) in the 
stomach releases B-12 from protein.  In the duodenum, B-12 is then bound to intrinsic 
factor (IF), a factor released from parietal cells of the stomach.  The B-12-IF complex is 
absorbed in the ileum of the small intestine.  Inadequate IF for B-12 binding and 
absorption is often a result of the autoimmune response called pernicious anemia, and 
may ultimately lead to B-12 malabsorption (29).  Conditions which decrease HCl levels, 
such as gastritis and hypochorhydria associated with medications, prevent B-12 from 
being released from food proteins and ultimately prevent absorption of B-12 (5). 
 
Assessment of B-vitamin nutriture  
 Literature currently indicates that serum B-12 is a poor marker for detecting B-12 
adequacy (21, 32).  Biomarkers like methylmalonic acid (MMA) and 
holotranscolbalamin have been recommended as more sensitive indicators.  MMA levels 
above 376 nmol/L appear to be indicative of B-12 deficiency as well as serum 
holotranscobalamin greater than 45 pmol/L.  Holotranscobalamin is stated to be a useful 
measure to detect earlier B-12 imbalances (33).   
When assessing B-12 status using holotranscobalamin or MMA, creatinine must 
be taken into account.  Creatinine is a product created from the breakdown of creatine a 
component of muscle and is often an indicator of kidney function (34).   Hvas and Nexo 
(34) reported that increases in serum creatinine by 100 µmol/L doubled MMA, 
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holotranscobalamin, and other B-12 metabolites.  Therefore, assessment of B-12 
should include corrections for creatinine level, as creatinine is often elevated for reasons 
not related to vitamin deficiency. 
 
 
FIGURE 1.2  Vitamin B-12 absorption (35) 
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In 2000, the prevalence of gastritis was estimated to be between 20%-50% of 
elderly based on the diagnosis criteria used.  The Framingham study found 24% of 
individuals 60-69 years old and 37% of individuals over the age of 80 to had gastritis.  It 
is important to note that only in the most severe cases of gastritis does intrinsic factor 
secretion become limited to the point of vitamin B-12 malabsorption.  Gastritis may lead 
to bacterial overgrowth which can also affect absorption of B-12 due to the bacteria’s 
uptake of the vitamin.  The condition can also affect folate absorption by decreasing 
hydrochloric acid in the stomach therefore, increasing the pH in the stomach and small 
intestine.  The slight increase in pH can make a noteworthy decrease in releasing B-12 
from protein and decreases folate absorption (26).  Lower levels of B-vitamins and higher 
homocysteine levels are also common in the elderly (36).   
  
Folate fortification 
In 1998, in response to overwhelming evidence that levels of folate was 
associated with increased risk for neural tube defects, all flour and uncooked cereal-grain 
products in the US were required to be fortified with folic acid at a level of 140 
micrograms/100 grams (28, 37).  In response to folate fortification, it is estimated that 
neural tube defects prevalence and incidence has decreased 15-50% in the US (28).  In 
the Framingham cohorts it was reported that subjects who did not take supplements with 
B-vitamin had 38% higher RBC folate post folate fortification (38).  Prior to fortification, 
4.9% were deficient in folate and post-fortification only 1.9% folate deficient.  The 
authors noted that this increase in serum folate may be masking B-12 deficiencies and 
causing irreversible neurologic damage (38).   
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In the face of concerns that high levels of folate may mask B-12 deficiency in 
elderly, the 140 µg of folate fortification level was chosen with the intent that only a few 
people would exceed 1 mg per day.  The upper limit of 1 mg per day was somewhat 
arbitrarily selected by the Institute of Medicine as an improbable level to produce 
masking.  Kim (28) stated that this is controversial due to the fact that others argue intake 
less than 1 mg may result in the masking of a B-12 deficiency.  Kim also states that other 
countries have failed to follow the US in fortifying with folate due to this debate despite 
its obvious benefits among pregnancy and birth defects (28).   
It should be noted that 50-95% of folate content in food is estimated to be lost in 
storage, preparation, or manufacturing processes.  And some have questioned whether the 
average person in the US is receiving adequate folate even post-fortification (39).  One 
study found that though dietary intake of folate was low that serum levels were not below 
normal indicating that the subjects were not yet in negative nutrient balance.  It is 
difficult to assess B-vitamins intake from food because there are many problems with 
getting accurate measurements of folate intake.  There are over 150 different forms of 
folate and determining bioavailable portions in different foods has variable accuracy (39).  
Bioavailability of food folate has been reported to vary anywhere from 10-98% (40).  
Exact differences in absorption between folate fortified foods and folate naturally 
occurring in foods is also unknown.  It appears synthetic forms of folic acid whether 
fortified to food or in supplement form are more bioavailable than folate from food (41).  
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Folate and B-12 masking 
Because interactions between B-12 and folate were considered potentially 
problematic, the level of fortification was chosen to be 140 micrograms of additional 
folic acid per day.  Given typical consumption patterns, this level of fortification should 
result in very few instances of intake greater than 1 mg, the level set by the Institute of 
Medicine as the upper limit, and at which masking of B-12 deficiency may be 
problematic.  This has not been proven and there is inconsistency in actual evidence 
identifying the level where masking would likely occur (28).   
Morris et al. (7) found that 4% of their study’s participants, who included elderly 
men and women from the US National Health and Nutrition Examination Survey, had 
both a low vitamin B-12 and high folate status.  This status was related to increased risk 
for anemia and greater cognitive impairment.  Interestingly, when B-12 status was 
normal, high serum folate was associated with protection against cognitive impairment 
rather than possible harm (7).  If 4% of the elderly in the US are similar to this 
subsample, then ~1.8 million may be at risk for decreased cognition related to folate and 
B-12 imbalances (42). 
Smith (42) presents multiple questions on issues surrounding this topic, such as 
the questions: “should the issue of fortifying food with vitamin B-12 be reopened in those 
countries that have already fortified certain foods with folic acid?” and “should countries 
considering folic acid fortification defer a decision until more is known about the 
interaction between folate and vitamin B-12 status?” (42).   Though the main focus of our 
research is to shed light on B-vitamins and AD, results from this project may provide 
insight about this issue. 
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Though some studies have identified association between B-vitamins and 
cognition, these findings are far from consistent, and several, including some who have 
examined these associations in large prospective studies, have observed no association 
between dietary folate and B-12 and cognition or AD incidence (30, 43-49).   
 
INTRODUCTION TO THE CACHE COUNTY MEMORY, 
HEALTH, AND AGING STUDY 
 
The Cache County Study began in 1994 with joined efforts by Duke University, 
Utah State University and Johns Hopkins University.  It included 5,092 participants from 
Cache County, Utah, located in the northern part of the state.  As a longitudinal cohort 
study with four waves of data collected presently, the Cache study has many strengths.  
One strength of the Cache study is its high rates of participation with 89.9% of those 
eligible participating at baseline to 79% during last wave.  Participants of the Cache 
County Study were men and women 65 years of age or older in 1995.  Most (91%) of the 
participants are members of The Church of Jesus Christ of Latter-day Saints (LDS).  This 
religion urges its members to practice healthy behaviors such as excluding the use of 
tobacco and alcohol.  Not surprising, the population has a longer life expectancy than the 
general US population.  The 1990 U.S. Census reported the median life expectancy in 
Cache County at age 65 was highest in the nation, almost ten years greater than the 
national average (50, 51).  This population is also well educated with more than 80% 
having completed at least a high school education.   The Cache population also has lower 
rates of migration and is known for large close families, factors helpful for participant 
retention throughout the study. 
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The original purpose of the study was to examine the prevalence and incidence 
of dementia and by cognitive screening and careful clinical assessment of the participants 
over a period of time.  Requirements for participation in the study included a history void 
of a central nervous system disorders or current psychiatric disorder and completion of a 
dementia screening.  At baseline, 4,298 subjects were dementia-free.  Approval from 
institutional review boards at USU, Duke, and Johns Hopkins were obtained, and each 
participant signed an informed consent form before participating.  
Each subject’s cognitive status was screened at the baseline and subsequent 
follow-ups using the Modified Mini-Mental State Examination (3MS) or rated by 
knowledgeable informants using an Informant Questionnaire for Cognitive Decline 
(IQCODE).  The genotype at the locus for Apolipoprotein E (APOE) gene was 
determined from DNA from a buccal scraping collected from subjects.  Subjects scoring 
less than 87 points on the 3MS or higher than 3.27 on IQCODE and all subjects older 
than 90 years were further examined in clinical follow-up using the Dementia 
Questionnaire (DQ) administered by trained nurses.  The DQ is an inventory of cognitive 
symptoms, functional impairments, and medical conditions relevant to dementia.  The 
suspected cognitive impaired group was supplemented with a sample of individuals 
randomly selected from those deemed non-demented at baseline and both groups were 
asked to complete a comprehensive clinical assessment that included examination, blood-
pressure, neurologic examination, psychometric testing, and review of cognitive 
symptoms and medical histories. 
The clinical data was reviewed by a geropsychiatrist and neuropsychologist who 
then assigned diagnoses of dementia, other cognitive disorders, or normal cognitive 
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status.  Those suspected of dementia underwent further testing and final dementia 
diagnoses were decided by a consensus conference of experts including a 
neuropsychologist, a board-certified geriatric psychiatrist and the examining nurse and 
technician. 
 
 
FIGURE 1.3 Cache County study design 
 
Clinical assessment at the baseline interview identified 368 individuals out of the 
original 5,092 subjects as having dementia.  Prevalent cases of dementia will be excluded 
in our analyses of risk associated with incident AD. 
Usual dietary intake was assessed using a food frequency questionnaire (FFQ) at 
baseline (in 1995) and during a follow-up assessment (wave 3) in 2002-2004 (see 
appendix A and B).  The FFQ used was modeled after the Harvard Nurses’ Health Study 
FFQ, and its format has been validated for replicated uses.  FFQ’s are useful for large 
population-based studies because they can be administered by an interviewer (wave 3) or 
done by the participant by themselves (wave 1).  They are relatively inexpensive and are 
a quick method for assessing usual intake, using only one inquiry.  A list of 142 foods or 
groups of foods were provided and participants noted the frequency with which they 
consumed the food or food group by the following categories:  less than 1 per month, 1-3 
1995: Baseline 
5,092 elderly in Cache  
County enrolled in study 
1995-1997: Wave 1 
5,092 screened 
3,829 completed FFQ 
1998-2000: Wave 2 
3,411 screened 
 
2002-2004: Wave 3 
2,344 screened 
2,144 completed FFQ 
357 prevalent dementia 
246 prevalent AD 
193 incident dementia 
128 incident dementia 
318 incident dementia 
202 incident AD 
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times per month, 2-4 times per month, 1 time per week, 2-4 times per week, 5-6 times 
per week, 1 time per day, 2-3 times per day, 4-5 times per day, and 6 or more times per 
day. 
To calculate intake of a specific nutrient, the nutrient content of each food per 100 
grams was multiplied by the frequency of daily consumption of each food.  This number 
was then summed over all food items.  A database containing nutrient content of foods 
reported by participants in the CCMS with nutrients per 100 grams was created using a 
standard nutrient database, the Food Processor created by ESHA Research and data from 
food manufacturers (52).  The Food Processor version 7.02 (1997) consists of over 
30,000 foods (there are >32,000 foods in more current versions) and is updated 
frequently.   It includes specific brands and types of foods such as “Wendy’s chili” or 
“Kellogg’s Corn Flakes,” although many of these foods are not available through the 
USDA.  Approximately ¼ of the foods come from the USDA database, the rest come 
from manufacturers and restaurants.  The Food Processor also allows new recipes to be 
entered and version 8.2, which food composition data should correlate with wave one 
data has 45 nutritional components available for analysis (more recent versions have 
closer to 164) (52).  We created a food table of the food choices seen on the FFQ to be 
used to calculate daily intakes. 
The software FoodCalc, was used for analysis and quantification of the FFQ data.  
The FoodCalc program is public-domain software from the Danish Cancer Registry 
written by Jesper Lauritsen, and is an effective tool for evaluating large amount of FFQ 
data (53).   Once a table of foods representative of the foods in the FFQ was compiled 
and computed per 100 grams, Foodcalc was used to total nutrients by individual’s intake 
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per day, by specific foods or food groups, and overall totals by all individuals for all 
foods consumed (53).      
 
RESEARCH QUESTIONS 
The analyses presented in this thesis will attempt to address the following 
research questions: 
1. Are dietary intakes of B-vitamins including folate, vitamin B-12, and vitamin B-6, 
from both food and supplemental sources associated with incidence of dementia 
and AD? 
2. Do interactions between intakes of these nutrients mediate the association of 
individual B-vitamins and incidence of AD? 
3. Are these associations modified by potential confounders such as gender, age, 
education level, other dietary and health behaviors, and apoe-4 genotype? 
 
OBJECTIVES 
 The objectives of this study are as follows: 
1. Create a nutrient database of all foods reportedly consumed in wave 1 and wave 3 
of the Cache County Memory Study with measurement of nutrients per 100 gram 
servings.  Use the Foodcalc program to compute the amount of nutrients 
consumed per day for each individual. 
2. Examine associations between food folate, supplemental folate, and total folate 
with incident dementia and incident AD.   
3. Investigate effects of varying intake levels vitamin B-12 and folate with AD 
controlling for B-6.  Examine associations accounting for confounding factors 
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such as age, sex, education, APOE genotype, weight status, history of physical 
activity, history of comorbidities, and other dietary factors. 
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CHAPTER 2 
LITERATURE REVIEW OF THE RELATIONSHIP BETWEEN FOLATE,  
OTHER B-VITAMINS AND ALZHEIMER’S DISEASE 
 
 
ABSTRACT 
 
 The influence of dietary intakes and nutrition status on cognitive health in the 
elderly has been the focus of much research.  Folate and other B-vitamins have 
specifically been considered due to their known roles in one-carbon metabolism.  
Mechanistically it is possible these nutrients may also affect incidence of Alzheimer’s 
disease (AD) by contributing to decreased production of S-adenosyl methionine (the 
primary methyl donor for the brain) formation, elevated homocysteine (a possible 
neurotoxin) and through abnormal DNA production (which requires certain forms of 
folate).  Elderly populations have higher rates of folate and B-vitamin deficiencies than 
other age groups and may contribute to higher rates of elevated serum homocysteine 
observed among elderly.  Hyperhomocysteinemia has been found to be associated with 
cognitive impairment and AD.  Whether elevated levels of homocysteine are merely a 
marker of poor diet or insufficient folate and B-vitamins or a contributing factor for 
development of AD is unclear.  Studies of associations between dietary intake and serum 
levels of B-vitamins, homocysteine, cognitive decline, and incidence of AD have 
reported inconsistent findings.  Dietary folate, B-12, and B-6 have been studied as 
possible independent risk factors for cognitive health, but it may be possible that the 
effects these micronutrients have on cognitive health is mediated by interactions between 
these nutrients.   
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RELATIONSHIP BETWEEN FOLATE, B-VITAMINS  
AND ALZHEIMER’S DISEASE 
 
 
Introduction 
 
Many of the roles of folate, vitamin B-12 and vitamin B-6 in one-carbon 
metabolism have long been well established.  The relationship between these 
micronutrients and homocysteine levels has been observed in many studies, and elevated 
homocysteine has been associated with several diseases including heart disease and 
Alzheimer’s disease (AD) (1, 2).  However, it is unclear whether elevated homocysteine 
is a marker or risk factor of disease.  Whether folate, B-12 and B-6 status are independent 
risk factors of cognitive decline via metabolism of homocysteine or other metabolites and 
ultimately Alzheimer’s disease is unknown.  It is possible that the existence of the disease 
may result in poorer diet, which would offer an alternative explanation to the observed 
associations of lower serum levels of folate, B-12 and B-6 in individuals with AD. 
It is particularly interesting to examine relationships between AD and B-vitamins 
among elderly populations for two obvious reasons.  First, AD is a disease of aging and 
occurs at higher rates with increasing age.  Secondly, elderly populations have increased 
rates of deficiencies of B-vitamins.  Vitamin B-12 deficiency is of particular concern 
among elderly populations due to high rates of food bound malabsorption of B-12.  B-12 
must be released from proteins by acids in the gastrointestinal tract, decreases in acidity 
caused by gastritis, medication, and other conditions in this population prevent absorption 
of vitamin B-12.  Gastritis is more commonly seen in elderly due to increased bacterial 
overgrowth (3) and leads to increased use of gastric-acid blocking medications (4) which 
decrease the release of B-12 from food.  This is not an issue with dietary supplement 
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intakes of B-12.  Elderly also have higher rates of pernicious anemia, an autoimmune 
reaction where intrinsic factor (IF) production is decreased.  After B-12 is released from 
proteins, IF binds B-12 making it available to be transported across the gut membrane 
(4).  Pernicious anemia decreases absorption of both food and supplemental forms of B-
12.  
The association between folate, vitamin B-12, vitamin B-6 and cognitive health is 
not widely agreed upon.  Researchers have observed positive associations, no association, 
and occasionally negative associations.  Some studies suggest that higher intake of folate 
is protective against cognitive decline (5, 6); others report possible harmful effects of 
higher folate intake (6, 7).  Most researchers in the field agree that more prospective 
studies with adequate power are required to bring further light to the discrepancies 
observed thus far.     
 
 
FIGURE 2.1 One-carbon metabolism (Adapted from Lim, 2005) (8) 
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Proposed Mechanisms 
The relationships between B-vitamins and one-carbon metabolism are evident in 
many reactions of one-carbon metabolism (see Figure 2.1).  Key steps where B-vitamins 
are involved include folate and B-12 role in the methylation of homocysteine to 
methionine; which in turn is converted into S-adenosyl-methionine (SAM), a methyl 
donor for many reactions.  B-6 is required for alternate pathways of homocysteine 
metabolism and folate cycling (9).  The conversion of 5,10-methylene-THF to 5-methyl-
THF, the methyl donor for homocysteine, is catalyzed by the enzyme 
methyltetrahydrofolate reductase (MTHFR).  This reaction is irreversible and the 
conversion of 5-methyl-THF to THF is dependent on vitamin B-12.  Therefore, B-12 
deficiency traps folate as 5-methyl-THF and is appropriately known as the methyl-folate 
trap.  This condition of B-12 deficiency and adequate folate also results in a lack of 
coenzyme forms of folate needed for DNA synthesis and red blood cell maturation (10, 
11).   
Vitamin B-6 may become more or less important to homocysteine metabolism 
depending of status of other B-vitamins.  B-6 acts as a cofactor to an alternative pathway 
of homocysteine metabolism; homocysteine is converted to cystathionine rather than 
methionine in this reaction.  In one experiment, folate deficient rats were loaded with 
methionine which increased SAM and in turn signaled homocysteine catabolism despite 
inadequate folate.  In rats who were also B-6 deficient, the upswing of SAM was not 
accompanied by homocysteine remethylation; indicating B-6 may be crucial for 
maintaining homocysteine equilibrium in folate deficient states (12). 
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 Deficiencies of B-vitamins leading to disturbed one-carbon metabolism are 
theorized to enhance AD progression or cognitive decline in multiple ways.  The most 
prominent association between one-carbon metabolism and AD is probably the theory 
that elevated homocysteine induces oxidative stress which may lead to neurotoxicity (13, 
14).  Hyperhomocysteinaemia, may result from deficiencies of B-vitamins singularly or 
in combination and has been observed in numerous studies concerned with cognition (6, 
9).   
The prevention of homocysteine remethylation to methionine also leads to 
decreased formation of SAM.  SAM deficiency in turn may disrupt a number of key 
methylation reactions required for normal brain functioning affecting proteins, membrane 
phospholipids, neurotransmitters, and DNA structure (6, 9, 15, 16).  The functioning of 
SAM has been observed to be inhibited by surplus of S-adenosylhomocysteine (SAH) 
which is also caused by halted homocysteine metabolism (1).   SAH has also been 
observed at abnormal levels in individuals with AD similar to homocysteine and B-
vitamins like folate, B-12, and B-6 (15). 
Glutathione is a key antioxidant with the brain and is formed from a series of 
reactions that originate with homocysteine.  Several of the reactions leading to production 
of glutathione require vitamin B-6 and SAM.  This is another potential source of 
increased neural damage linked to one-carbon metabolism (13).  Finally, as was briefly 
mentioned earlier B-vitamin deficiencies may lead to what is known as the methyl-folate 
trap.  This may limit availability of folate metabolites needed for DNA formation and has 
been implication in breaks in DNA was may contribute to neurologic defects (6, 17).  
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Diet and serum biomarkers of B-vitamin status 
Studies involving dietary intakes of B-vitamins and related serum outcomes have 
established strong relationships.  In 1996, Tucker et al. (18) published their examination 
of the relationship between the dietary intakes and plasma levels of folate and 
homocysteine in the Framingham cohort.  The top contributors to dietary folate were 
breakfast cereal, fruit and vegetable intake, and other fortified foods.  They found clear 
dose relationships between increasing quintiles of breakfast cereal, fruit and vegetable 
intake, plasma folate and lower levels of homocysteine (18).   
A study done by Tucker et al. published in 2004 (19) examined the relationship of 
B-vitamin intake and homocysteine levels in a trial involving varying levels of fortified 
ready-to-eat-cereal.  The 215 subjects were age 55-85 and had no history of hypertension, 
anemia, asthma, cancer or cardiovascular disease or digestive disease and no regularly 
consumption of multi-vitamin mineral supplements, B-vitamin supplements, or highly 
fortified breakfast cereal.  The subjects were randomly divided into intervention and 
placebo groups; the intervention group received a fortified cereal (440 µg folate, 1.8 mg 
vitamin B-6, and 4.8 microgram B-12) for 12 weeks and the placebo a cereal similar in 
calories, fiber, carbohydrate, and other B-vitamins for the same time period.  The results 
showed a significant difference in homocysteine levels between the two groups.  
Homocysteine concentrations were significantly lower and B-vitamin concentrations 
were significantly higher among those consuming the folate fortified cereal (p < 0.001) 
(19).   
Manilow et al. (20) examined the effects of varying folate levels in ready-to-eat-
breakfast cereals in a study similar to Tucker et al (19).  Three cereals with equal levels 
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of B-6, B-12 and varying amounts of folic acid were given to a group of men and 
women with coronary artery disease (CAD).  The subjects were randomly divided and the 
study was double-blind and placebo-controlled.  Results showed increasing intake of folic 
acid from ready-to-eat-cereal resulted in increase plasma folate and decrease in 
homocysteine levels (20).   
In the Framingham cohort, 65% of the elevated homocysteine cases were found to 
have inadequate dietary folate or B-12 and B-6, with smaller effects (21).  The study also 
examined total homocysteine in relation to an overall vitamin status.  The subjects were 
divided into five categories; the first category represented individuals in the 70th 
percentile or better for all three B-vitamins (folate, B-12, and B-6) including intakes from 
supplements.  The fifth category included subjects with intakes below the 30th percentile 
for B-vitamin intakes; indicating those with the lowest intake of B-vitamins had the 
highest prevalence of hyperhomocysteinemia at six times that of those in the first 
category (22).   
 Major food sources of folate have been reported to include foods such as ready-
to-eat cereals, legumes, orange juice, and leafy greens (23).  A study examining 
consumption patterns of 680 white, elderly men and women from the Boston area found 
four dietary patterns that could be characterized by either high intake of 1) alcohol, 2) 
milk, cereals, and fruits, 3) bread and poultry, and 4) meat and potatoes (24).  Those in 
the high consumption of meat and potatoes had the lowest folate and B-6 vitamin levels. 
Those in the group with high intake of milk, cereals, and fruits had the best nutrient 
profiles including folate and B-vitamins (24). 
 
  
33 
 
Homocysteine and cognition 
Elias et al. (25), discussing the Framingham Offspring Study, suggested several 
theories for the relationship between increased age, homocysteine, and cognition.  First, 
is that longer exposure to toxic effects of homocysteine causes increased neural damage.  
The second theory is that confounding effects caused by deficiency in a vitamin cofactors 
such as folate or vitamin B-12 exist, indicating elevated homocysteine as more of a 
marker of poor nutrition than a direct cause for disease (25). 
Hyperhomocysteinemia may increase amyloid B-peptide toxicity and increase 
neuron excitotoxic insults, especially in the hippocampal region (10).  Several studies 
have linked elevated homocysteine levels to increased cognitive decline (6, 26-33).  
Morris (16) cited several, including Bell et al. (34), Clarke et al. (35), McCaddon et al. 
(15), and Morris et al. (36), but, one study cited by Morris found no association between 
homocysteine and cognitive decline.    
 
In vitro studies 
 
 The effect of homocysteine on nerve cells has been examined to determine a 
possible neurotoxic effect.  Boot et al. (37) treated neuroepithelial cells with folic acid 
and homocysteine.  The folic acid increased differentiation and outgrowth where addition 
of homocysteine inhibited neural crest differentiation.  This study was focused on 
modeling the known effects of folic acid and homocysteine in young pregnant women, 
but do demonstrate interesting effects in regard to homocysteine and folic acid on neural 
cells and may have implications for normal neural cell function and growth in the brain 
(37).    
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 Ho et al. (38) treated cortical neurons with homocysteine and discovered a 
myriad of responses that may link hyperhomocysteinemia to cognitive impairments.  The 
cultures had increased reactive oxygen species, phosphorylated-tau protein, externalized 
phosphatidyl serine indicating cell death, calcium influx suggesting excitotoxicity, and 
DNA strand breakage.  They also observed decreased levels of SAM, indicating 
inhibition of methylation reactions (38). 
 Another study induced homocysteinylation (incorporation of homocysteine into 
proteins during translation) onto individual serum proteins (39).  Treatment appeared to 
damage proteins (albumin, gamma-globulin, fibrinogen, transferrin, and alpha2-
macroglobulin) and inactivated the enzymes methionyl-tRNA synthetase and trypsin 
(39).  This study suggests possible metabolic and biochemical abnormalities which may 
occur in the presence of excess homocysteine. 
 
Animal studies 
 
It is clear that homocysteine is related in some way to increased risk for chronic 
diseases like atherosclerosis, stroke, and Alzheimer’s but it is whether a risk factor or 
simply a risk marker for disease is less clear.   In one mouse model, apoE deficient mice 
were fed one of four diets.  The first group received a control diet with adequate B-
vitamins including folate, B-12 and B-6 (40).  The second and third groups were designed 
to induce B-vitamin deficiencies and hyperhomocysteinemia with or without methionine.  
And, the fourth diet was a B-vitamin enriched diet.  After eight weeks, cognition and 
memory was measured using the Morris Water Maze test.  Inadequate dietary B-vitamin 
diets did result in decreased plasma levels of B-vitamins, moderately decreased SAM 
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concentrations in the brain and severely elevated homocysteine in plasma.  The mice 
on these diets were found to have significant cognitive impairments (40).  Kruman et al. 
(11) found that elevated homocysteine increased hippocampal neurons likelihood to 
excitotoxic and oxidative injury in rat studies.   
Another mouse model found B-vitamin deprivation (for 45 and 60 days) to be 
associated with hyperhomocysteinemia and a decrease of SAM/SAH ratio (41).  This was 
accompanied by an increase in amyloid-β deposition and cognitive impairments in maze 
tasks (41).  Bernardo et al. (42) found that hyperhomocysteinemia induced diets were 
associated with decreased cognition and increased neurodegeneration in mice that over-
produce APP. 
Other animal studies have explored the effects of one-carbon metabolism gene 
mutations or deletions; ultimately leading to elevated homocysteine.  Chen et al. created a 
mouse model with the MTHFR gene deleted (43).  They found the associated metabolic 
outcomes of the mutation varied based on tissue location.  SAM concentrations remained 
unchanged in the liver but were significantly decreased in the brain.  SAH concentrations 
were significantly elevated in both locations.  Interestingly, methylation was only 
significantly impaired in the brain (43).  Application of these results to humans is 
cautioned because the level of elevated homocysteine in this model is much higher than 
would be seen in a B-vitamin deficient or hyperhomocysteinemia model in humans.  The 
study does suggest severely elevated levels may have large impacts on brain biochemistry 
and metabolism (43). 
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Cross-sectional studies 
 The famous Nun Study reported on sixty nun’s from convents in the US 
(midwest, east, and southern areas) with the objective of comparing brain infarcts, areas 
of cell death,  and clinical manifestation of AD (44).  The nuns came from similar 
environment, had similar nutritional habits, and ranged in ages from 75-100.  The brains 
were dissected and examined post mortem for vascular changes and damage and 
increased severity of dementia was found in nuns with significant brain infarcts.  Half the 
nuns (45) had neuropathological lesions of AD and folate was the only nutritional factor 
examined out of 18 that was negatively correlated with the atrophy (13, 46). 
 A case-control study involving 55 non-cognitively impaired, 81 mildly impaired, 
and 92 diagnosed AD or vascular dementia subjects (average age ~75) explored the 
relationship of homocysteine, B-vitamins and cognition (21).  Participants came from a 
Memory Clinic of the Ospedale della Beata Vergine, Mendrisio, Switzerland.  Quadri et 
al. (21) included a mildly impaired group for the purpose of exploring the question of 
whether elevated homocysteine exists prior to AD diagnosis suggesting its role as a risk 
factor or if it has only been observed as a marker or as a cause of vascular damage.  This 
study found those with the lowest tertile of serum folate had higher odds (OR 3.1) of 
dementia and cognitive impairment, and there was an inverse association between folate 
and homocysteine.  Results from this study indicated that folate deficiency and 
hyperhomocysteinemia may be present prior to the onset of dementia.  This study found 
no relationship between vitamin B-12 and cognitive decline but examined serum levels of 
cyanocobalamin which has been noted as a less indicative marker of B-12 status than 
holotranscobalamin or methylmalonic acid (MMA) (21). 
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In 2002, Duthie et al. (47) recruited survivors of two waves of Scottish Mental 
Surveys (years 1932 and 1947).  From the 186 and 148 survivors gathered from each 
wave, they observed positive associations between serum folate, B-12 and scores from 
the Mini Mental State Examination (MMSE).  Negative associations were seen between 
both vitamins and homocysteine levels.  In addition, homocysteine was negatively 
associated with other tests of cognition including Raven’s Progressive Matrices (RPM), 
digit symbol (DS) subtest, and block design (BD) subtest (47).  
 Lindeman et al. (48) analyzed 883 Hispanic and non-hispanic whites males and 
females, ages 65 or older, from Bernalillo County, New Mexico to examine relationships 
of vitamin serum markers and cognitive decline.  Serum folate, vitamin B-12 and vitamin 
C status were measured and compared to cognitive function.  Usual dietary intake was 
estimated using a Food Frequency Questionnaire (FFQ).  Cognitve function was assessed 
using a mixture of tests including the MMSE, WAIS-R Digits Forward, Fuld Object 
Memory Evaluation, clock drawing, two Color Trial Making Tests.  There was a 
significant association between dietary intake of folate and serum folate measures (p < 
0.001) and dietary B-12 and serum B-12 (p < 0.05).  The strongest associations were 
between folate status and various measures of cognition (p = 0.002).  Lower folate (<11.1 
nmol/L) status was associated with lower cognitive scores compared with normal folate 
status.  Serum B-12 was not associated with cognitive score (48). 
In the Normative Aging Study, Riggs et al. (31) reported decreased folate and 
vitamin B-12 levels to be related to lower spatial copying skills in 70 men ages 54-81 
from the Boston area.  Cognition was assessed using the MMSE, verbal fluency and 
constructional praxis adapted from the revised Wechsler Adult Intelligence Scale and the 
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CERAD batteries.   Low B-12 (p = 0.04), folate (p = 0.003), and elevated 
homocysteine (p = 0.0009) were all related to poor spatial copying skills.  They also 
found elevated homocysteine (>12.6 µmol/L) to be a stronger predictor than folate and B-
12 for spatial copying skill impairment (31).   
In a recently published article, Morris et al. (10) reported serum folate (<59 
nmol/L) and low B-12 status (serum vitamin B-12 concentration <148 pmol/L or a serum 
methylmalonic acid concentration >210 nmol/L) to be related to increased risk for anemia 
(odds ratio (OR): 2.7; 95% CI: 1.7, 4.2) and cognitive inpairment (OR: 2.5; 95% CI: 1.6, 
3.8) compared to those with normal B-12 status.  In a comparison of those with low B-12 
and high serum folate (>59 nmol/L) the odds of anemia (OR: 3.1; 95% CI: 1.5, 6.6) and 
cognitive impairment (OR: 2.6; 95% CI: 1.1, 6.1) was increased.  This supports the 
theory that high folate masking may be masking a B-12 deficiency.  The analysis 
included 1459 men and women ages 60 and older from the 1999-2002 US National 
Health and Nutrition Survey.  Cognition was assessed using the Digit Symbol Coding test 
and the MMSE (10). 
 
Prospective studies 
 
 Homocysteine levels were first found to be related to arteriosclerosis in 1969 by 
McCully who observed hyperhomocysteinaemia and arterial damage in two children 
(21).  Since then, hyperhomocysteinaemia has been associated with increased risk for 
heart disease, stroke, and cognitive function decline in observational and clinical trials 
(19, 49).  Factors associated with hyperhomocysteinaemia include genetic mutations, 
vitamin deficiencies, renal and other diseases, drugs, and increased age (45).  The 
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Framingham Heart Study found that 29% (n=885) of the original free living cohort, 
age 40-83 years old, had hyperhomocysteinaemia (homocysteine concentration >14 
umol/L) (18, 19).  Suggesting that elevated homocysteine is common among the elderly 
groups.   
 
Studies examining cognitive decline and serum markers 
The MacArthur Studies of Successful Aging included 499 high-functioning 
persons ages 70-79 from Durham, North Carolina; East Boston, Massachusetts; and New 
Haven, Connecticut (28).  Cognitive decline was assessed using a battery of cognitive 
tests including the Boston Naming test, perception and reproduction of spatial 
associations, Delayed Recognition Span Test, Wechsler Adult Intelligence Scale-
Revised, and abstract concept formation.  Researchers found persons in the lowest 
quartile of plasma folate (1.17 to 3.15 ng/mL) had 1.6 times the risk for cognitive decline 
over 7 years (28).   
The Leiden 85 plus Study is a cohort of 599 elderly subjects from the 
Netherlands, 85 years of age and older with a mean four year follow up (50).  Mooijaart 
et al. (50) investigated the relationships between serum levels of folate, B-12, 
homocysteine and rate of cognitive decline.  A series of cognitive tests were used to 
assess decline including the MMSE, Stroop test, a letter digit coding test, and word recall 
test.  No association between any of the serum markers and cognitive decline was 
identified.  One limitation put forward by the authors was the use of serum vitamin B-12 
concentrations as assessment for B-12 status, which is considered a poorer marker of 
metabolic vitamin B-12 deficiency (50). 
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Another study involving a larger span of ages (30-80 years) in 144 men and 
women from the Netherlands for 6 years examined the relationship between plasma 
homocysteine, B-vitamins and cognitive decline (6).  Cognition was assessed using the 
Letter-Digit coding test, Stroop test, Word Learning Test total and delayed recall. They 
found no relationship between serum levels of homocysteine, B-12 and folic acid and rate 
of decline at any measurement point over the 6 years (6).   
 
Studies examining cognitive decline and dietary intake 
The Chicago Health and Aging Project (CHAP) study involved 3718 AD free 
participants older than 65 years from the Chicago area (7).  Usual dietary intakes were 
estimated using a 139-item FFQ.  Cognition was assessed using the East Boston Tests of 
immediate and delayed recall, the MMSE, and the Symbol Digit Modalities Test.  In a 6-
year follow-up, Morris et al. (10) found that those in the top quintile of total folate intake 
(median 742 µg per day) had more than twice the rate of cognitive decline compared to 
the lowest quintile (median, 186 µg per day).  The top food folate quintile (median, 382 
µg per day) was associated with faster decline in an adjusted model.   High total B-12 
intake was associated with slower cognitive decline in the oldest participants (10).  
Studies examining cognitive decline, serum 
markers and dietary intake 
 
Only one study to date has examined cognitive decline, serum markers and 
dietary intake (51).  In 2005, Tucker et al. (51) published a paper on a larger group from 
the Normative Aging Study that included 321 men age 50-85 years old that were 
followed for over 3 years.  The objective of the study was to examine associations 
between dietary and serum B-vitamin measures with cognition.  Cognition was assessed 
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using the MMSE, verbal fluency and constructional praxis adapted from the revised 
Wechsler Adult Intelligence Scale and the CERAD batteries.  Diet was assessed using a 
126-item FFQ.  Decreased spatial copying was significantly associated with low plasma 
measures of all three vitamins (folate, B-12, and B-6), elevated homocysteine, and dietary 
intakes of each vitamin. They found higher dietary folate (<339µg/d) to be protective of 
verbal fluency decline and hyperhomocysteinaemia (>11nmol/L) related to a decline in 
recall memory (p < 0.05) (51). 
Studies examining incident dementia/AD  
and serum markers 
 
The Conselice Study of Brain Aging (CSBA) is a prospective population-based 
survey of 816 dementia-free Italians with a mean age of 74 years (52).  Dementia was 
diagnosed using the Diagnostic and Statistical Manual of Mental Disorders-IV clinical 
criteria.  Cox proportional hazards regression modeling accounting for covariates such as 
time, sex, genotype, education, etc. was used to determine relationships between 
homocysteine and incident AD.  An association between baseline homocysteine, risk of 
newly diagnosed dementia and AD was examined after a 4-year period (1999-2000 to 
2003-2004).  The results suggested that both elevated homocysteine (>15µmol/L) 
(HR:2.08 95% CI: 1.31, 3.30 for dementia and HR: 2.11; 95% CI: 1.19, 3.76 for AD) and 
low serum folate (<11.8 nmol/L) (HR: 1.87; 95% CI: 1.21, 2.89 and HR: 1.98; 95% CI: 
1.15, 3.40) were independently related to risk for both dementia and incidence of AD.  
This study did not find an association with B-12 and incident dementia or AD (30, 52).  
This study adjusted for serum creatinine, but did not use the holotranscobalamin or MMA 
measurement, better measures of B-12.   
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Luchsinger et al. (53) also examined homocysteine and risk for AD in the 
Washington Heights-Inwood Columbia Aging Project (WHICAP).  A group of 909 
elderly participants, average age 77.2 were randomly chosen from a group who had 
received Medicare assistance and followed for about 1.5 years.  The results showed no 
relationships between incidence of AD and high serum homocysteine, nor any association 
between elevated homocysteine and cognitive decline over time (p = 0.31).  The 
relationships were significantly confounded by age.  One limitation disclosed by the 
authors was a lack of power to detect modest associations (53). 
A study by Wang et al. (54) involved 370 non-demented participants from the 
Kungsholmen Project.  Participants were men and women from Stockholm, Sweden, ages 
75 years, plus and were followed for three years.  The objective of the study was to 
examine serum folate and B-12 in relation to incident AD.  They did find significant, 
nearly doubled risk for AD, among participants who were deficient in either folate (<10 
nmol/L) or vitamin B-12 (<150 pmol/L).  The relative risk (RR) among those with low 
folate or B-12 for AD was 1.4 (95% CI: 1.2, 3.5) (6).  
Though other studies have not reported similar findings when examining serum 
vitamin levels and incident AD, if the results of Wang et al. (54) are to be accepted, 
further consideration for whether dietary intakes are actually reflected in serum levels and 
how closely they are reflected is required.  Several studies have shown positive 
associations between dietary or supplemental intake of B-vitamins and associated serum 
biomarkers, including Tucker et al. (P < 0.0001) (19), Manilow et al. (P = 0.045) (20), 
Selhub (P < 0.01) (22).     
  
43 
 
An earlier study (2002) by Seshadri et al. (33) on the Framingham offspring 
cohorts found hyperhomocysteinaemia present in subjects pre-diagnosis of AD.  The 
analysis included 1092 dementia-free participants with a mean age of 76 years.  
Participants were followed for eight years.  Those with hyperhomocysteinaemia had 
increased risk for both incident AD and dementia (RR 1.8 {95% CI: 1.3, 2.5} and 1.4 
{95% CI: 1.1, 1.9} respectively) (33).    
 
Studies examining incident dementia/AD  
and dietary intake of B-vitamins 
 
A prospective cohort study among the participants of the (WHICAP) studied 965 
dementia-free elders, 65 years and older from the northern Manhattan area (5).  
Luchsinger et al. (5) examined relationships between dietary intake of folate, B-12 and B-
6 and incident AD.   A 61-item FFQ was used to assess nutrient intake.  Dementia and 
AD diagnoses were made using the Diagnostic and Statistical Manual of Mental 
Disorders.  After six years, 192 participants developed AD.  The highest quartile of folate 
intake (>489.7 µg) was related to lower risk for AD (HR: 0.5; 95% CI: 0.3, 0.9); there 
was no associations between B-12, B-6 and AD (5, 6). 
Morris et al. (55) observed no association between incident AD and dietary intake 
of B-vitamins among participants of the CHAP.  The CHAP study, previously mentioned, 
is a prospective study which involved 1,041 initially AD free biracial elders, age 65 plus, 
from the Chicago community.  Dietary assessment was made using a 139-item FFQ.  AD 
diagnoses were made based on tests of the Consortium Established for Research on 
Alzheimer’s Disease (CERAD).  Limitations of this study include many of the dietary 
assessments were collected after the baseline interviews and no serum markers were 
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collected.  The CHAP study did identify a relationship between dietary intake of B-
vitamins and protective factors for AD such as younger age, white race, higher education, 
etc. (55). 
Another study, by Corrada et al. (56), with a sample of 579 non-demented elderly 
volunteers ages 49-93 from the Baltimore Longitudinal Study of Aging, found higher 
total folate intake was associated with lower risk for AD (RR: 0.41; 95% CI: 0.22 0.76) 
(6).  Dementia was diagnosed using the Diagnostic and Statistical Manual of Mental 
Disorders, third edition and AD diagnosis made using criteria from the National Institute 
of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and 
Related Disorders.  Diet was assessed from seven day dietary records kept by 
participants.  The subjects were followed for an average of 9.3 years. No association was 
found between total intake of vitamin B-12 and AD (6).  
 
Studies examining cognitive decline, incident  
dementia/AD and serum markers 
 
Researchers from the Sacramento Area Latino Study on Aging have also recently 
published a paper on this topic (27).  The study included a cohort of 1170 Mexican 
Americans ages 60-101 who were followed over 4-5 years.  Haan et al. (27) used 
proportional hazards modeling to examine associations between serum markers (RBC 
folate, plasma B-12, homocysteine, and serum creatinine) and incident dementia and 
cognitive impairment without dementia (CIND) assessed using the MMSE and Verbal 
Episodic Memory test.  They found hyperhomocysteinaemia (>13 µmol/L) to be an 
independent risk factor for dementia (HR: 1.58; 95% CI: 1.88, 2.83).  High vitamin B-12 
(>498 pg/mL), but not folate, was associated with low risk of homocysteine related 
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dementia (dementia related to elevated levels of homocysteine) or CIND (HR: 2.5; 
95% CI: 1.31, 4.54).    This study did adjust for serum creatinine levels but did not use 
the holotranscobalamin or MMA measure.  The authors note that though other studies 
have failed to look for or find the same relationship of B-12 and dementia, the 
relationship has been seen enough that further investigation should be done. Morris et al. 
(7), Tucker et al. (51), Wang et al. (54), and Hann et al. (27) have noted associations 
between B-12 and dementia.  
 
Possible explanations for conflicting results 
 
Though several studies have shown a negative relation between B-12 status and 
homocysteine levels, when Refsum and Smith (57) examine the relationship measuring 
the active form of B-12, holotranscobalamin, participants with AD were found with 
significantly lower levels of cobalamin.  Since 80% of total cobalamin is bound to 
haptocorrin and is not available to the cells, holotranscobalamin is a better indicator of B-
12 status in relation to deficiency effects (57).  Another study using the 
holotranscobalamin measure involving 1000 elderly from the UK found independent 
relationships between cognitive decline and low serum holotranscobalamin with high 
homocysteine.  They noted that relationships were significantly higher with that measure 
compared to that of vitamin B-12 (58).   
A case-control study mentioned earlier by Quadri et al. (21) stated that one reason 
that may account for other studies finding differing results (relationship between 
homocysteine, B-vitamins and dementia) is the fact that many studies did not adjust for 
serum creatinine when looking at homocysteine.  Quadri et al. (21) mentioned that two 
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other studies which did adjust had similar results to their study.   Adjusting for serum 
creatinine is important due to the highly correlated relationship between serum creatinine 
and homocysteine (and other B-12 markers).  Increased creatinine by 100 µmol/L 
doubled levels of MMA, holotranscobalamin, and homocysteine in one study (59).  
Creatinine may be elevated for a number of other reasons unrelated to vitamin deficiency. 
 
TABLE 2.1 
Summary of prospective studies 
Authors Design Subjects Methods Results 
Studies Examining Cognitive Decline and Serum Markers 
Kado et al. 2005 (28) Cohort, serum 
homocysteine 
(hcy), B-
vitamins related 
to cognitive 
scores in high-
functioning 
elders, mean 
follow-up of 7 
years 
N = 499 men 
and women age 
70-79, from NC, 
MA, CN 
involved in the 
MacArthur 
Studies of 
Successful 
Aging 
Subjects 
administered 
Boston Naming 
test, perception 
and reproduction 
of spatial 
associations, 
Delayed 
Recognition Span 
Test, Wechsler 
Adult Intelligence 
Scale-Revised, 
and abstract 
concept formation 
 
Low folate status 
increased risk for 
cognitive decline 
Mooijaart et al. 2005 (50) Cohort, serum 
hcy, folic acid, 
vit B12 related 
to cognitive 
decline, mean 
follow-up of 4 
years 
 
N = 599 men 
and women 
from the Leidan 
85-Plus Study, 
from the 
Netherlands 
Subjects assessed 
using *MMSE, 
Stroop test, a 
letter digit coding 
test, a word recall 
test 
No associations 
Teunissen et al. 2003 
(60) 
Cohort, serum 
hcy, folate, vit 
B-12 
associations 
with cognitive 
decline, mean 
follow-up of 6 
years 
 
 
 
 
N = 144 men 
and women, 
ages 30-80, from 
the Netherlands 
Subjects 
administered 
Letter-Digit 
coding test, 
Stroop test, Word 
Learning Test 
total, and delayed 
recall 
 
no associations 
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TABLE 2.1, CONTINUED 
Summary of prospective studies 
Authors Design Subjects Methods Results 
Studies Examining Cognitive Decline and Serum Markers 
Ravaglia et al. 2005 (52) Cohort, plasma 
hcy, folate, and 
vit B-12 to 
Incident 
dementia and 
AD, with mean 
follow-up of 4 
years 
N = 816 
dementia-free, 
Italians, mean 
age 74 from the 
Conselice Study 
of Brain Aging 
(CSBA) 
Subjects assessed 
by qualified 
clinicians 
Elevated hcy and 
low serum folate 
were related to 
increased risk for 
dementia and AD.  
No associations 
were found 
between B-12 and 
incident 
dementia/AD 
 
Luchsinger and Mayenx 
2004 (61) 
Cohort, plasma 
hcy associations 
with incident 
AD, mean 
follow-up 1.5 
years 
N = 909 men 
and women 
mean age 77.2 
from the 
Washington 
Heights Inwood 
Columbia Aging 
Project 
(WHICAP) 
 
Subjects assessed 
by qualified 
clinicians 
No associations 
Wang et al. 2001 (54) Cohort, plasma 
vit B-12 and 
folate to 
incident AD, 
mean follow-up 
3 years 
N = 370, men 
and women 
older than 75 
from Stockholm, 
Sweden 
participating in 
the 
Kungsholmen 
Project 
 
Subjects assessed 
by qualified 
clinicians 
Low levels of B-
12 or folate were 
independently 
related to double 
the risk for 
incident AD 
Seshadri et al. 2002 (33) Cohort, serum 
hcy to incident 
dementia and 
AD, mean 
follow-up 8 
years 
N = 1092 
dementia free 
participants with 
a mean age of 
76 from the 
Framingham 
cohort 
 
 
Subjects assessed 
by qualified 
clinicians 
Elevated hcy 
related to 
increased risk for 
both incident AD 
and dementia 
Studies Examining Incident Dementia/AD and Dietary Intake 
Luchsinger et al. 2007 
(5) 
Cohort, dietary 
intake of folate, 
vit B-12 and vit 
B-6 with 
incident AD, 
mean follow-up 
of six years 
N = 965 men 
and women 65 
years and older 
from the 
Washington 
Heights Inwood 
Columbia Aging 
Project 
(WHICAP) 
Subjects assessed 
by qualified 
clinicians 
Highest intake of 
folate was related 
to lower risk for 
AD.  No 
associations 
observed between 
vit B-12, vit B-6 
and AD. 
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TABLE 2.1, CONTINUED 
Summary of prospective studies 
Authors Design Subjects Methods Results 
Corrado et al. 2005 (56) Cohort, dietary 
intake of folate, 
vit B-12 to 
incident AD, 
mean follow-up 
average of 9.3 
years 
N = 579 men 
and women ages 
49-93 from the 
Baltimore 
Longitudinal 
Study of Aging 
Subjects assessed 
by qualified 
clinicians 
No associations 
found with B-12, 
higher folate and 
B-6 were 
independently 
associated with 
decreased risk.  
Folate was the 
only associated 
vitamin in an 
model with all 
three vitamins 
Studies Examining Cognitive Decline, Incident Dementia/AD and Serum Markers 
Hann et al. 2007 (27) Cohort, serum 
hcy, folate, vit 
B-12 to incident 
dementia and 
cognitive 
decline, follow-
up of 4-5 years 
N = 1170 
Mexican 
American men 
and women ages 
60-101 from the 
Sacramento 
Area Latino 
Study on Aging 
Assessed by 
qualified 
clinicians and 
using the MMSE 
and Verbal 
Episodic Memory 
test. 
High hcy was 
associated with 
increased risk for 
dementia.  High 
B-12 was 
associated with 
low risk for 
homocysteine 
related dementia 
or cognitive 
impairment 
*Mini-Mental State Examination 
 
 
 
Human intervention trials 
 
Studies examining folic acid only  
 
 In 2007, a paper published on the FACIT (folic acid and carotid intimamedia 
thickness trial) reported possible protective effects in cognitive performance from 
supplementation of folic acid.  This was a large randomized, double-blind, control trial 
that had 818 men and women with elevated homocysteine and normal B-12 markers, ages 
50-70, divided into placebo and supplemental groups.  The supplemental group received 
800 µg of folic acid per day (twice the recommended amount) for three years.  They had 
576% higher serum folate and 26%  lower homocysteine levels after the three years and 
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significantly better changes in memory (measured by the Verbal Learning Test) 
compared to the placebo group (26).   
Fioravanti et al. (62) reported cognitive function improvement in 30 participants 
with abnormal cognitive decline and low folate levels (3 ng/ml or less) supplemented 
with folic acid for 60 days.  The improvement was positively correlated with degree of 
folate deficiency at baseline (62).    
 
Studies examining folic acid and other B-vitamins 
 
Another clinical study found supplementation with neither vitamin B-12 nor a 
combination of B-12 and folic acid supplementation provided any improvement in 
cognitive function (63).  Participants were 195 elderly, aged 70 plus, from different parts 
of the Netherlands, with mild vitamin B-12 deficiency, defined by either serum B-12 
between 100-200 pmol/L or serum B-12 between 200-300 pmol/L, MMA greater than 
0.32 µmol/L, and serum creatinine greater than 120 µmol/L.  Groups were randomized to 
receive 1000 µg B-12 plus 400 µg folic acid, 1000 µg B-12 alone, or placebo for 24 
weeks.  Cognition was assessed using the Mini-Mental State Examination (MMSE), and 
Clinical Dementia Rating (CDR) (63). 
McMahon et al. (64) found B-vitamins had no effect on cognition in a supplement 
trial of 1000 µg of folic acid, 500 µg of vitamin B-12 and 10 mg of vitamin B-6.  
Participants included 276 healthy elderly men and women, ages 65 and older, with 
homocysteine levels greater than 13 µmol/L.  After two years of intervention, 
homocysteine levels were significantly lower in controls but there was no difference in 
cognition between the groups (64). 
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The Vital Trial Collaborative group randomized 149 individuals at high risk for 
dementia into three treatment groups of aspirin, a variety of vitamin supplements (folic 
acid, vitamin B-12, vitamin E, and vitamin C), and placebo.  The subjects were assessed 
to be at increased risk for dementia using MMSE and Alzheimer’s Disease Assessment 
Scale-Cognitive subscale (ADAS-Cog).  B-vitamins had no effect on cognitive function, 
but did lower homocysteine by 30% (6).   
  Two older trials found some positive effects from B-vitamin supplementation.  
Bryan et al. (65) saw the improvement in cognitive function (assessed by a battery of 
different cognitive tests) using short-term supplementation in 211 healthy women of 
various ages for 60 days.  Participants received 750 µg folic acid, 15 µg vitamin B-12, 
and 75 mg of vitamin B-6 or placebo.   
 In a small supplementation trial involving 33 subjects exhibiting with mild-
moderate dementia and a mean age of 78.4, researchers examined the effects of 
supplementing with 500 µg folic acid and 1 mg of vitamin B-12 a day for 2 months on 
homocysteine and cognition using the MMSE.  Blood samples were collected before and 
after supplementation.  Five participants who were deemed severely demented and unable 
to follow study procedures were excluded.  Of the remaining 28 participants, two groups 
were formed based on baseline homocysteine levels cut at 19.9 µmol/L.  Subjects with 
mild-moderate dementia and elevated homocysteine at baseline did benefit from the 
supplementation regime and exhibited higher MMSE scores post treatment.  Those 
without elevated homocysteine did not improve cognitively (29). 
The relationship between B-vitamins, homocysteine, and dementia is not 
universally accepted.  Morris et al. (66) strongly state that current research does not 
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validate associations between B-vitamins and AD with the exception of B-12 
deficiency and cognitive decline.  B-12 deficiency has been widely accepted to be 
characterized by cognitive and psychiatric disturbances due to B-12’s role in 
metabolizing methylmalonic acid (4, 15, 66).    
 
TABLE 2.2 
Summary of human intervention trials 
Authors Design Subjects Methods Results 
Studies Examining Folic Acid Only  
Durga et al. 2007 
(26) 
Randomized 
clinical trial, 
effects of folic acid 
supplementation 
on cognitive 
performance 
N = 818, men and 
women ages 50-
70, with elvated 
homocysteine 
(hcy) from the 
Folic acid and 
carotid 
intimamedia 
thickness trial 
(FACIT) 
 
Supplemental 
groups receive 800 
µg of folic acid per 
day for three years.  
Cognition was 
measured using the 
Verbal Learning 
Test 
Supplemental 
group had 576% 
higher serum folate 
and 26% lower hcy 
levels.  They also 
had significantly 
better changes in 
memory 
Fioravanti et al. 
1997 (62) 
Randomized 
clinical trial, effect 
of folic acid 
supplementation in 
people with 
abnormal cognitive 
decline and low 
serum folate 
N = 30 participants 
with abnormal 
cognitive decline 
and low serum 
folate 
Participants 
received 15 mg of 
folic acid for 60 
days.  Cognition 
was assessed using 
Randt memory 
test, acquisition 
and recall, delayed 
recall, memory 
index, encoding 
factor, cognitive 
efficiency, and 
attention efficiency 
Cognitive 
improvement was 
seen in the group, 
degree of 
improvement was 
negatively 
correlated to 
degree of baseline 
folate deficiency 
Studies Examining Folic Acid and Other B-vitamins 
McMahon et al. 
2006 (64) 
Randomized 
clinical trial, 
effects of a variety 
of supplements 
(folic acid, vit B-
12, vit  B-6) on 
cognitive decline 
and incident AD 
 
 
N = 276 healthy 
elders age 65 years 
and older with 
elevated hcy 
levels. 
Groups were 
randomized to 
receive 1000 µg 
folic acid, 500 µg 
of B-12, and 10 
mg of B-6 for two 
years 
 
 
 
 
There was a 
significant 
decrease in hcy 
levels over 
controls but no 
difference in 
cognition between 
the groups 
TABLE 2.2, CONTINUED 
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Summary of human intervention trials 
Authors Design Subjects  Methods Results 
Clarke et al. 2003 
(67) 
Randomized 
clinical trial, effect 
of supplementation 
with folic acid and 
vit B-12 versus 
placebo on 
cognitive function 
N = 149, high risk 
of dementia men 
and women from 
the Vital Trial 
Collaborative 
group 
Groups were 
randomized to 
receive 2 mg folic 
acid, 1 mg vit B-12 
or placebo.  
Cognition was 
assessed using the 
MMSE and the 
Alzheimer's 
Disease 
Assessment Scale 
Cognitive subscale 
(ADAS-Cog) 
 
Supplemented 
group had hcy 
levels decreased by 
30%, they saw no 
difference in 
cognitive function 
Bryan et al. 2002 
(65) 
Randomized 
clinical trial, effect 
of B-vitamin 
supplementation 
on cognitive 
decline 
N = 211 healthy 
women, from 
various ages 
Groups were 
randomized to 
receive 750 µg 
folic acid, 15 µg 
vit B-12, and 75 
mg of vit B-6 or 
placebo.           
Cognition was 
assessed using 18 
different cognitive 
tests 
 
Supplemented 
group had 
improvement in 
cognitive function 
Nilsson et al. 2001 
(29) 
Randomized 
clinical trial, effect 
of supplementing 
with 500 µg of 
folic acid and 1 mg 
of vit B-12 on 
homocysteine and 
cognition 
N = 33 subjects 
with mild-
moderate 
dementia, mean 
age 78.4, refer to 
the Psychogeriatric 
department of the 
Lund University 
Hospital 
Subjects received 
500 µg of folic 
acid and 1 mg of 
vit B-12 for 2 
months.  Cognitive 
assessment was 
done using the 
MMSE 
Those with 
elevated 
homocysteine at 
baseline did 
benefit from 
supplementation as 
seen by increase 
MMSE scores 
*Mini-Mental State Examination 
 
 
Meta-analyses of supplemental trials 
A meta-analysis of randomized trials done by the Homocysteine Lowering 
Trialists’ Collaboration included 2596 subjects from 25 controlled randomized studies 
published from 1993-2003.  They found supplementation with 0.5 to 5 mg of folic acid a 
day for a mean of eight weeks lowered homocysteine levels by 25% among individuals 
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with normal folate status (12 nmol/L).  The addition of .02-1 mg of B-12 showed 
further reduction by 7%.  B-6 and betaine were less effective at reducing homocysteine 
(45).  The timing of this meta-analysis is important because most trials were done prior to 
fortification of the food supply with folic acid.   Since fortification the results in the 
studies examine by the meta-analysis may be less robust due to the decline in folate 
deficiency prevalence. 
Shah et al. (68) examined results from studies on homocysteine, cognitive 
functioning, hormone levels, and exogenous estrogen use in women published from 1993 
to 2005.  Elevated homocysteine was regularly associated with cognitive decline. They 
concluded that there is not sufficient evidence to suggest that homocysteine levels are 
linked to cognitive decline, and that dietary supplementation with B-vitamins assists with 
homocysteine level control without evidence that this change has any effect on cognition 
(68). 
Ellison et al. (69) identified six studies meeting criteria to analyze relationships 
between serum folate, B-12, homocysteine and cognitive impairment.  Three case-control 
studies and three cohort studies with subjects over 60 years old were included.  The 
majority of the studies used the MMSE to assess cognition.  Total homocysteine was 
found to be associated with cognitive scores; folate and B-12 status was not (69). 
 
Meta-analyses of cardiovascular-health related trials 
 Efficacy of folic acid supplementation on cardiovascular health related outcomes 
has been more extensively studies than trials on cognitive outcomes.  Results from meta-
analyses of these trials were also inconsistent. 
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de Bree et al. (70) conducted a meta-analysis on folic acid trials and vascular 
reactivity spanning from 1966-2005.  Only fourteen of over 150 trials met exclusion 
criteria.  Folic acid doses ranged from 600-5000 µg/d.  Folic acid appeared to increase 
endothelial function 1.08 (95% CI: 0.57,1.59; P = 0.0005).  This may have implications 
for reducing heart disease (70).  Data from this study include trials from both pre- and 
post-fortification.  
A recent meta-analysis of folic acid, homocysteine and cardiovascular disease by 
Wald et al. (71) examined cohort studies and randomized trials.  Results from sixteen 
cohort studies show comparable relationships between decreases in homocysteine and 
risk of heart disease.  Among the seven randomized trials short term benefits were 
observed but Wald et al. state statistical power is lacking preventing conclusiveness of 
these results (71).   
 Bazzano et al. (72) investigated studies from 1966 to 2006 on folic acid 
supplementation and risk for cardiovascular diseases.  Studies that met the criteria 
included a total of 16,958 participants with vascular disease.  The relative risks for folic 
acid supplemented participants with cardiovascular disease, coronary heart disease, 
stroke, and all-cause mortality were as follows: 1.04 (0.92-1.17) , 0.86 (0.71-1.04), and 
0.96 (0.88-1.04) respectively.  The authors concluded there is not sufficient evidence 
suggesting folic acid supplementation reduces risk for  vascular diseases (72) . 
 
Supplements versus dietary sources 
Supplementation with B-vitamins while examining cognitive function has been 
explored with varying results.  The inconsistencies found between these studies are vastly 
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due to the differences in methods and procedures.  Supplementation trials summarized 
by a task force on nutrition and cognitive decline reported 50% of reviewed trials saw 
improvements in cognitive function and B-vitamin supplementation (6).  The other half 
of the trials saw no improvements (6).  Selhub et al. (1) mentions results from studies by 
Lendenbaum et al. and Martin et al. which report improvement in cognitive recovery in 
B-12 deficient subjects with supplementation of the vitamin, suggesting poor vitamin 
status may partially be the cause of cognitive impairment seen in some elderly (1).   
Studies that have examined dietary intake of B-vitamins in relation to cognitive 
health also have varying results.  Luchsinger et al. (5) did observe decrease risk for 
incident AD/dementia in participants who consumed high amounts of total folate (food 
plus supplement), but the relationship was not significant with high intake of folate from 
food only.  Morris et al. (55) and Corrado et al. (56) did not see a reduction of risk for 
incident AD.  The conflicting results are not limited to positive and no associations.  
Morris et al. (7) reported that high dietary folate intake was related to faster cognitive 
decline in the CHAP group.   
The bioavailability of supplemental and fortified folic acid sources appears to be 
higher than that of folate found naturally in food (73).  Actual assessment of absorption 
of folate and other B-vitamins is very difficult.  There are over 150 different forms of 
folate and common conditions such as gastritis are known to inhibit B-12 absorption.  
One source noted that 50-95% of folate in food is estimated to be lost in storage, 
preparation and manufacturing (74).  Based on the current literature there is not enough 
evidence to suggest supplementation with B-vitamins in persons with adequate serum 
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levels for improvement in cognitive impairment.  Supplementation in deficient persons 
is warranted and may provide cognitive improvements.  
  
CONCLUSION 
 
As stated by Morris et al. (55) despite the extensive amount of attention given to 
folate, other B-vitamins and homocysteine in the area of cognitive health among the 
elderly, there is not enough evidence that a causal relationship between B-vitamins and 
cognitive health exists (55).  It is also evident that the results from these many studies are 
often contradictory and inconsistent because study designs and methods vary greatly.  
Among clinical trials duration of supplementation, control of diet, dosage, combination of 
vitamins used, and types of assays used to assess nutriture vary greatly.  Measures of 
cognitive status also vary greatly.  It may be possible that improvements may be seen in 
only certain areas of cognitive health, which may be detected by only certain tests.  There 
are many limitations to assessing usual dietary intake of B-vitamins.  Dietary assessment 
tools such as the FFQ, commonly used provide less precise estimates of usual intake than 
more burdensome multiple day recall a recording methods.  In addition, bioavailability 
between forms of B-vitamins like folic acid and B-12 vary.  Finally, amongst the elderly, 
common medical conditions like gastritis are known to alter absorption of B-vitamins.    
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CHAPTER 3 
DIETARY FOLATE, OTHER B-VITAMINS AND INCIDENT ALZHEIMER’S 
DISEASE:  THE CACHE COUNTY MEMORY, HEALTH,  
AND AGING STUDY1  
 
ABSTRACT 
Background B-vitamins, especially folate, are of interest in regards to cognition due to 
their roles in one-carbon metabolism. 
Objective To examine associations between dietary and supplemental folate, vitamin B-
12 and vitamin B-6 and incident Alzheimer’s disease (AD) among elderly men and 
women. 
Design This study analyzed data collected from the Cache County Memory, Health and 
Aging Study, a longitudinal study of men and women elders 65 years and older who were 
residents of Cache County, Utah.  Multistage clinical assessment procedures were used to 
identify incident cases of AD.  Dietary data was collected using a 142 item Food 
Frequency Questionnaire.  Cox Proportional Hazards modeling was used to determine 
hazard ratios across quintile intake of micronutrients.  The models controlled for the 
effects sex, education, physical activity, BMI, energy intake, and other covariates. 
Results 202 participants were diagnosed with incident AD during follow-up (1995-
2004).  There were no observed differences in risk of AD or dementia by increasing 
quintiles of total intake of folate, vitamin B-12, and vitamin B-6.  Users of supplemental 
folic acid were more likely to have healthy diet and lifestyle factors although no 
association was observed those between using <400 µg/d and dementia or AD. 
                                                 
1
 Coauthors: Nelson C, Wengreen HJ, Munger RG, and Corcoran CR. 
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Conclusion Dietary intake of B-vitamins from food and supplemental sources, 
individually or combined appear unrelated to incidence of dementia and AD.  Further 
studies examining associations between dietary intakes, biomarkers of status and 
cognitive endpoints are warranted. 
 
INTRODUCTION 
 The prevalence of Alzheimer’s disease (AD) is expected to more than double in 
the next fifty years with the aging of the baby boomers (1, 2).  In 2004, it was reported 
that 2% of the population of industrial countries population were affected by AD (2).  AD 
is currently the third most costly disease in the US coming in behind cancer and heart 
disease (3).  In 2003, AD increased the cost of health care by 80-100 billion dollars (3). 
AD is undoubtedly an age-related disease, but risk for AD, the severity, and rate 
of decline are influenced by genetic as well as modifiable environmental factors 
including diet (3, 4).  Although many dietary factors likely play a role in cognition, 
relationships between folate, vitamin B-12, and vitamin B-6 have recently gained interest 
(5). 
 Mechanistically there are several explanations for the possible relationship 
between B-vitamins and AD.  Folate, vitamin B-12 and vitamin B-6 are key methyl 
carriers and cofactors of one-carbon metabolism (6).  Deficiencies of folate and B-
vitamins are known to be accompanied by increased levels of homocysteine, an 
intermediate of one-carbon metabolism (7).  In vitro studies, homocysteine has been 
identified as a possible neurotoxin, as it may increase oxidative stress and damage 
leading to neuronal cell death (4, 8).  During the last ten years research involving 
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increased risk for heart disease and hyperhomocysteineamia has been widely published 
(9-12).  A similar relationship between homocysteine and cognition is also being 
extensively investigated (5, 7, 8, 13-24).   
 Several mechanisms of disrupted one-carbon metabolism may link risk for AD to 
B-vitamins, including decreased concentrations of S-adenosyl-methionine (SAM).  SAM 
is the primary methyl carrier for methylation reactions in the brain and is formed from 
methionine.  Methionine comes from the diet and is formed from homocysteine which 
requires adequate folate and vitamin B-12 (25).  Finally, folate in particular may affect 
cognitive health due to its essential role in nucleotide formation.  Deficiency may alter 
normal DNA/RNA synthesis, which may impact neuron formation and function (25).  
 The elderly population is not only at increased risk for AD but also have higher 
rates of B-12 deficiency (26).  B-12 deficiency is characterized by macrocytic anemia, 
neuropathy, and irreversible neurologic damage in severe cases.  B-12 is a cofactor for 
two enzyme reactions.  In addition to B-12’s role in one-carbon metabolism, as a part of 
the methionine synthetase, B-12 also acts as a cofactor to the reaction converting 
methylmalonic acid to succinyl-CoA (27).  Absorption of vitamin B-12 is dependent on 
the environment of the gastrointestinal tract and is often impaired among elderly with 
gastritis or drugs that decrease gastric acid like antacids (28).  Vitamin B-12 is naturally 
only found in animal products.  The Framingham study reported that 24-37% of the 
cohort could be diagnosed with gastritis depending on diagnoses criteria used (6).  About 
20% of the cohort was folate deficient, 20-25% were B-12 deficient, and about 20% were 
B-6 deficient in the early 1990’s.  One in twenty elders over 65 and one in ten over 75 
were found to be B-12 deficient in a population from the United Kingdom (26).  Serum 
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levels of B-12 are often used to assess status, but inconsistency in the use of 
biomarkers to diagnose vitamin B-12 deficiency may be contributing to underestimates in 
actual B-12 deficiency prevalence (29).   
Since the mandate to fortify cereal and grain products in the US with folic acid, a 
decreased prevalence of folate deficiency has been observed (30).  With the increase of 
folate intake and status, many have voiced concern of a potential effect of folate masking 
deficiencies of other B-vitamins, primarily vitamin B-12.  The “masking effect” is based 
on the observation that a vitamin B-12 deficiency diagnosis becomes more difficult as the 
main symptom, macrocytic anemia, it often alleviated with folic acid supplementation 
and simultaneously ‘masks’ the underlying B-12 deficiency which may lead to 
irreversible cognitive impairments depending upon the length and severity of the 
deficiency (31).  A study on data from NHANES observed participants with high serum 
folate in the presence of low vitamin B12 status had increased risk for both anemia and 
cognitive decline (32). 
 Research on this topic is inconclusive as many studies report conflicting results 
(5).  Among prospective studies high levels of folate intake, defined by intake more than 
557 µg/d has been identified as both harmful and protective in relation to cognitive 
decline and incidence of AD (24, 33).  Other studies have shown no relationship between 
folate, B-vitamins and AD (34).  The objective of this study is to examine relationships 
between folate, vitamin B-12, vitamin B-6 and incident AD, as well as to consider 
mediating effects of varied combinations of adequacy and deficiency of B-vitamins, 
among elderly participants of the Cache County Memory, Health, and Aging study with 
over nine years of follow-up.        
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SUBJECTS AND METHODS 
 
 
Subjects 
 
 The Cache County Memory Study is a population based prospective study of men 
and women who were living in Cache County, Utah and 65 years or older at the baseline 
assessment in 1995.  This cohort study followed a group of elders assessing cognition, 
general health, medical history, diet, pharmaceutical use, physical activity, education, etc.      
Of the 5,657 potential participants identified 89.7% were enrolled (n = 5092).   Baseline 
and subsequent screening interviews included self or proxy reports of demographic 
variables, medical history, occupational history, smoking or alcohol history, and 
information on family history. 
 Methods and procedures were reviewed by Institutional Review Boards at Utah 
State, Duke, and Johns Hopkins and all participants or legal caregivers signed an 
informed consent to participant. 
 
Outcome assessment 
 The main outcome was yes/no incident dementia and Alzheimer’s disease across 
nine years of follow-up.  Cognitive function was screened at baseline and three 
subsequent follow-up assessments (wave 1: 1997-1998, wave 2: 1998-2000, and wave 3: 
2002-2004) using a modified version of the Mini Mental State Examination (3MS) or 
among those unable to complete the 3MS were rated by knowledgeable informants using 
an Informant Questionnaire for Cognitive Decline (IQCODE).  Participants who scored 
lower than 87 on the 3MS or higher than 3.27 on the IQCODE and all subjects older than 
90 years of age were matched with controls from the remaining cohort and were further 
  
68 
 
assessed for cognitive status using a multi-staged clinical assessments.  The clinical 
data included results from the Dementia Questionnaire (DQ) and a clinical assessment 
which included an examination, blood-pressure measurement, neurologic examination, 
psychometric testing, and review of cognitive symptoms and medical histories.  The DQ 
is an inventory of cognitive symptoms, functional impairments, and medical conditions 
relevant to dementia administered by trained nurses.  The clinical evaluations were 
review by a geropsychiatrist and a neuropsychologist, who assigned dementia diagnoses, 
noncases, and other dementia diagnoses.  Those assigned a dementia diagnoses were 
further examined by a board-certified geropsychiatrist and completed a magnetic 
resonance imaging scan and laboratory tests.  Agreement of final diagnoses was 
performed by consensus conference of experts.  
 
Diet assessment 
An estimate of usual dietary intake at baseline was collected using a self-
administered Food Frequency Questionnaire (FFQ).  The FFQ used was modeled after 
the Harvard Nurses’ Health Study FFQ; its design has been test and validated for 
replicated use (35, 36).  It included sections surveying dietary supplement usage.   FFQs 
are useful for large population-based studies due to their ability to estimate average 
intake across long periods of time, to be self administered, and are relatively quick and 
inexpensive.  FFQ provide an assessment of usual dietary intake in a single 
administration.   
Using standard FFQ methodology, participants were asked to report the frequency 
they consumed one of the 142 foods or food groups.  The frequency of consumption 
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categories were as follows: Less than 1 per month, 1-3 times per month, 2-4 times per 
month, 1 time per week, 2-4 times per week, 5-6 times per week, 1 time per day, 2-3 
times per day, 4-5 times per day, 6 or more times per day. 
To calculate intake of a specific nutrient, the nutrient content of each food is 
multiplied by the frequency of consumption for each food.  Nutrient intake is then is 
summed over all food items for each individual.  A database containing foods reported by 
participants in the CCMS with nutrients per 100 grams was created.  Nutrient 
composition information was obtained from standard nutrient databases like the Food 
Processor (ESHA version 8.2) and time matched to the dates of the study (37).  The 
ESHA Food Processor version 8.2 (used for wave 1) consists of approximately 30,000 
foods (there are >32,000 foods in more current versions) and is updated frequently.   It 
includes specific brands and types of foods such as “Wendy’s chili” or “Kellogg’s Corn 
Flakes,” many of these foods are not available through the USDA.  Approximately ¼ of 
the foods come from the USDA nutrient composition database, the rest come from 
manufacturers and restaurants (37).   
The openware program known as FoodCalc, was used for quantification of the 
FFQ data.  The computational tool is public-domain software from the Danish Cancer 
Registry written by Jesper Lauritsen, and is an effective tool for evaluating large amounts 
of FFQ data (38).   Once a table of foods representative of the foods in the FFQ is 
compiled, Foodcalc will total nutrients by individuals intake per day, by specific foods or 
food groups, or overall totals by all individuals for all foods consumed (38). 
 Nutrient intake was adjusted for total energy intake using the residual method 
outline by Walter Willet (39).  Kilocalories are used as the independent variable and 
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absolute nutrient intake from food as the dependent variable in a regression model.  
Energy adjusted intakes of the nutrient of interest are calculated using residuals from the 
model summed with the mean caloric intake level of that nutrient (39).  Energy adjusted 
levels were summed with nutrient intake from supplements to obtain total intake of 
nutrients.   
 At baseline 5092 participants were screened using the 3MS; those who scored 
below the cutoff did not receive a FFQ.  Of the 4737, who were asked to complete the 
FFQ, 3829 (81%) completed and returned the questionnaire.  Of those, 197 were 
excluded based on later clinical diagnosis of prevalent dementia or implausible caloric 
intake (energy intake greater than 5000 kilocalories or less than 500 kilocalories per day).  
Thus, 3634 participants who were not demented and provided complete dietary data at 
the baseline interview are included in the analyses presented here.  In subsequent 
analyses an additional 116 participants with incidence of non-AD type dementia were 
also excluded, 3518 participants remained for the incident AD analysis.   
 
Statistical analysis 
The SPSS version 15.0 for Windows software program was used for all statistical 
analysis.   Exposure variables were defined using quintiles of total (food plus 
supplement) folate, B-12, and B-6 and folate and B-6 from food sources only.   Quintiles 
of B-vitamin intake were used because usual dietary intake was assessed using an FFQ 
which has better power to rank levels of intake of individuals than to assess actual intake 
levels.  Quintiles were assigned using a visual binning tool in the SPSS software 
program.  Additionally, degree of supplementation with folic acid and vitamin B-6 was 
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defined as more or less than 400 µg of folic acid/day or more or less than 2 mg of 
vitamin B-6/day.   Descriptive analyses were conducted using chi-square tests of 
independence for categorical variables and one-way ANOVAs to examine continuous 
variables.  Cox proportional Hazards modeling was used to evaluate risk of incident 
dementia and AD across increasing quintiles of total folate intake and other B-vitamin 
intake.  The time variable was defined as the age at event defined by the participant’s age 
at diagnoses of dementia, their current age if non-demented and remaining in the study 
and for those censored and no longer in the study, their age at death or last follow-up.  
The event variable was incident dementia or AD (dementia/AD=1 and noncase=0).   
Covariates used in the analysis were obtained from the baseline interview and 
included gender, level of education (less than high school education or greater than high 
school education), APOE genotype defined by (no copies or 1-2 copies), history of 
tobacco (ever/never) and alcohol use (ever/never), physical activity pattern (more than a 
few times per month or more or less than a few times per month), total caloric intake 
(kcal/day), self-reported comorbidities (history of diabetes (ever/never), myocardial 
infarction (ever/never), and stroke (no/probable) at baseline), and related dietary factors 
(folate, B-12, or B-6).  Associated dietary factors were included as continuous variables 
in the model of the main effect of other dietary factors.    
The Likelihood Ratio Test (LRT) was used to examine the fit of the models 
examining incident AD.  In the fully adjusted model (model 3), including total folate did 
not improve the fit of the model (p=0.67).  The same was true in models with folate from 
food only and in the model with folate from supplements only (p=0.30 and p=0.52 
respectively).  LRT also revealed no improvement in the strength of model 2 using total 
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folate, food folate, or folate from supplements (p=0.76, p=0.31, and p=0.59, 
respectively).  Including total B-12 and B-6 in models two and three did not improve fit 
of the models either.   
 
RESULTS 
 Two-hundred and two of the participants remaining in our analysis had developed 
Alzheimer’s disease by wave three.  Table 3.1 illustrates characteristics of the population 
by gender.  A larger proportion of women than men were enrolled in the study.  Women 
in the CCMS had higher rates of supplement use, 46% versus 39% (P < 0.001) and a 
significantly larger proportion had completed more than a high school education at 87% 
versus 82% (P < 0.001).  They also had significantly higher rates of incident AD at 3.5% 
versus 2.0% (P = 0.042).  Men in the CCMS were significantly younger (P < 0.001), 
consume more kilocalories (P < 0.001), had higher rates of MI at 17.5% versus 8.8% (P 
< 0.001) and also had higher rates of tobacco (P < 0.001) and alcohol usage (P < 0.001).  
Men also exercised more often than women at 89% versus 83% (P < 0.001). 
 Folic acid supplement use was defined as daily consumption of 400 µg of 
supplemental folic acid or more.  Folic acid supplement users were more likely to be 
women, have higher baseline 3MS scores, weigh less, and have better dietary patterns 
including eating less fat, more fiber, fruit and vegetables, and fish.  Folic acid supplement 
users were also more likely to have at least a high school education and to exercise more 
than were non supplement users (Table 3.2).  A high percentage of participants in Q4-5 
of total folate (food plus supplement) consumed supplements of folic acid and thus those 
in Q4-5 of total folate were more likely to be women, had more education, and eat 
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healthy diets with fruits, vegetables, and fish.   Table 3.3 illustrates population 
characteristics by quintiles of folate intake from food and supplemental sources.  Those in 
the top quintiles of folate intake also consumed more fruits, vegetables, and fish. 
 
TABLE 3.1 
Population characteristics by gender 
  Male Female 
  (n=1564) (n=2070) 
Food folate intake (µg/d)2 319 ± 126 321 ± 134 
Food B-12 intake (µg/d)2 5.99 ± 3.76 6.27 ± 4.69 
Food B-6 intake (mg/d)2 2.11 ± 0.70 2.27 ± 0.70*** 
Total folate plus supplement intake (µg/d)2 477 ± 256 506 ± 256*** 
Total B-12 plus supplement intake (µg/d)2 9.18 ± 10.96 10.00 ± 9.52* 
Total B-6 plus supplement intake (mg/d)2 6.65 ± 18.27 7.87 ± 21.38 
Dementia (%) 3.5  5.3 
Alzheimer's (%)  2.0 3.5* 
BMI (kg/m²) 26.40 ± 3.87 26.05 ± 4.82* 
Age (baseline) 74.19 ± 6.53 75.00 ± 6.75*** 
Total energy intake (kcals/d) 2049 ± 786 1882 ± 764*** 
Multivitamin supplement users (%) 38.6 45.8*** 
Folic acid supplement users (%) 4.5 4.3 
B-Complex vitamin supplement users (%) 9.0 12.1** 
Vitamin B-6 supplement users (%) 7.9 8.4 
Use Tobacco (% ever) 34.8 6.9*** 
Use Alcohol (% ever) 27.3 7.4*** 
Moderate Physical Activity (% Yes3) 89.0 83.0*** 
Stroke (% Probable/Uncertain) 4.5 3.5 
MI (% at baseline) 17.5 8.8*** 
Diabetes (% at baseline) 14.0 12.0 
ApoE alleles (% 1-2 copies) 32.3 30.9 
Education (% >High School) 81.5 86.6*** 
1
 ± SD (all such values). 
2Energy adjusted nutrients from food  
3Yes = a few times a month or more 
*p<0.05  
**<0.01 
***p<0.001   
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TABLE 3.2 
Population characteristics by folic acid supplement intake from any supplement source 
  No (< 400 µg/d) Yes (>/=400 µg/d) 
  (n=2207) (n=1427) 
Male (%) 45.7 39.0* 
Dementia (%) 8.7 8.9 
Alzheimer's (%)  5.5 5.9  
Average 3MS    
   Wave 1 90.97 ± 6.70 91.52 ± 6.14** 
   Wave 2 91.72 ± 7.96 92.34 ± 7.70* 
   Wave 3 90.18 ± 9.24 90.68 ± 8.28 
BMI (kg/m²) 26.38 ± 4.52 25.94 ± 4.29** 
Age (baseline) 74.69 ± 6.80 74.60 ± 6.47 
Total energy intake (kcals/d) 1936.71 ± 773.34 1980.16 ± 783.59  
Total folate intake (µg/d)1 320.03 ± 136.16 320.91 ± 121.43 
Total vitamin B-12 intake (µg/d)1 6.21 ± 4.20 6.05 ± 4.49 
Total vitamin B-6 intake (mg/d)1 2.16 ± 0.65 2.26 ± 0.79*** 
Total CHO (g/d)1 264 ± 37.7 268 ± 43.9*** 
Total Protein (g/d)1 86. 5 ± 17.7 87.8 ± 19.1* 
Total Fat (g/d)1 70.8 ± 13.3 68.4 ± 15.3***  
Total Fiber (g/d)1 19.1 ± 6.5 20.7 ± 7.7*** 
Folic acid from supp (µg/d)1 6.5 ± 34.6 431 ± 107*** 
Use Tobacco (% Ever) 18.5 19.6 
Use Alcohol (% Ever) 84.3 83.6 
Moderate Physical Activity (% Yes3) 84.2 87.7** 
Stroke (% Probable/Uncertain) 4.7 2.8* 
MI (% at baseline) 13.6 11.0* 
Diabetes (% at baseline) 13.3 12.1 
ApoE alelles (% 1-2 copies) 31.7 31.0 
Education (% > High School) 83.0 86.6** 
Servings of Fruit/day 2.53 ± 1.71 2.91 ± 2.24*** 
Servings of Vegetables (no potato)/day 3.49 ± 2.49 3.89 ± 2.76*** 
Servings of Dairy/day 2.20 ± 1.51  2.25 ± 1.52 
Servings of Fish/day 0.20 ± 0.22 0.22 ± 0.22** 
Servings of Grain/day 3.10 ± 1.70  3.05 ± 1.65 
Servings of Sweets/day 0.95 ± 1.06 0.90 ± 1.00 
Servings of Meat and Poultry/day 0.98 ± 0.65 1.02 ± 0.74 
1Energy adjusted nutrients from food and supplement (when applicable)  
2
 ± SD (all such values). 
3Yes = a few times a month or more 
*p<0.05 for difference across quintiles 
**<0.01 for difference across quintiles 
***p<0.001 for difference across quintiles 
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TABLE 3.3 
Population characteristics by quintiles of folate intake from food and supplemental 
sources1 
  Quintiles 
  1 2 3 4 5 
  (n=727) (n=727) (n=727) (n=727) (n=726) 
Total folate (µg/d)1 212 ± 56 303 ± 22 427 ± 66 656 ± 39 870 ± 178*** 
Male (%) 45.8 47.5 43.9 39.8 38.3** 
Dementia (%) 9.5 8.3 8.4 7.3 10.3 
Alzheimer's (%)  5.9 6.1 6.3 4.5 5.9 
Average 3MS       
   Wave 1 90.6 ± 6.7 91.3 ± 6.5 91.2 ± 6.5 91.6 ± 6.5 91.3 ± 6.2 
   Wave 2 92.3 ± 8.4 92.3 ± 7.7 91.8 ± 7.6 92.6 ± 8.0 92.2 ±7.6 
   Wave 3 89.5 ± 10.3 90.6 ± 8.6 90.1 ± 9.0 91.6 ± 7.4 90.5 ± 8.7 
BMI (kg/m²) 26.5 ± 4.7 26.3 ± 4.5 26.4 ± 4.4 26.1 ± 4.2 25.8 ± 4.4 
Age (baseline) 74.6 ± 6.9 74.6 ± 6.7 74.7 ± 6.7 74.3 ± 6.4 75.0 ± 6.6 
Total energy (kcals/d) 1931 ± 752 1956 ± 787 1909 ± 766 1971 ± 818 2001 ± 762 
MVM supp users (%) 1.7 2.4 21.5 90.3 94.6*** 
Folic acid supp users (%) 0.0 0.0 0.1 2.9 19.1*** 
B-Complex supp users (%) 4.8 4.7 6.6 13.9 23.8*** 
Vit B-6 supp users (%) 3.0 2.6 3.8 9.8 21.2*** 
Use Tobacco (% Ever) 20.3 19.4 15.5 18.9 20.4 
Use Alcohol (% Ever) 15.9 16.0 14.7 14.0 17.2 
Mod Physical Activity (% 
Yes3) 85.3 83.8 85.3 87.3 86.2 
Stroke (% 
Probable/Uncertain) 4.0 4.0 5.4 2.6 3.5 
MI (% at baseline) 14.1 13.0 13.3 12.5 10.0 
Diabetes (% baseline) 13.2 14.2 12.1 11.9 12.8 
ApoE alleles (1-2 copies) 35.3 31.2 28.7 30.7 31.4* 
Education (% > High 
School) 80.3 84.8 85.1 86.9 84.8* 
Servings of Fruit/day 2.55 ± 1.75 2.53 ± 1.67 2.55 ± 1.74 2.77 ± 2.51 3.00 ± 1.89*** 
Servings of Vegetables (no 
potato)/day 3.53 ± 2.67 3.53 ± 2.50 3.41 ± 2.35 3.81 ± 2.66 3.95 ± 2.79*** 
Servings of Dairy/day 2.18 ± 1.49 2.26 ± 1.52 2.16 ± 1.49 2.22 ± 1.56 2.27 ± 1.50 
Servings of Fish/day 0.21 ± 0.24 0.20 ± 0.20 0.20 ± 0.21 0.23 ± 0.21 0.23 ± 0.23* 
Servings of Grain/day 3.12 ± 1.68 3.10 ± 1.70  3.06 ± 1.74 3.06 ± 1.71 3.06 ± 1.58 
Servings of Sweets/day 0.95 ± 1.11 0.94 ± 1.01 0.92 ± 0.93 0.94 ± 1.09 .90 ± 1.02 
Servings of Meat & 
Poultry/day 0.95 ± 0.66 1.01 ± 0.65 0.97 ± 0.63 1.02 ± 0.71 1.02 ± 0.77 
1Energy adjusted nutrients from food and supplement  
2
 ± SD (all such values). 
3Yes = a few times a month or more 
*p<0.05 for difference across quintiles 
**<0.01 for difference across quintiles 
***p<0.001 for difference across quintiles 
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Table 3.4 illustrates nutrients intakes and food group patterns across quintiles 
of folate intake from food only.  Interestingly, there are no significantly differences 
between intake of nutrients or foods across quintile of intake of folate from food.  Top 
contributors of folate intake included ready-to-eat-cereal (RTEC), orange juice, bananas, 
romaine lettuce, and wheat bread.  There was no difference in risk across increasing 
quintiles of folate intake.   
 Cox proportional Hazards models were used to examine associations between B-
vitamins and incident dementia/AD.  No associations were observed between increasing 
quintiles of total folate and incident dementia or with AD in either unadjusted or adjusted 
models (Table 3.5-3.7).   Fully adjusted models included gender, education, number of 
apoE alleles, bmi, total calories, physical activity, history of alcohol and tobacco use, 
history of myocardial infarction, diabetes, stroke, and other B-vitamins (B-12, B-6).  In 
similar analyses total B-12 and B-6 from food and supplements combined were also not 
associated with incident dementia and AD adjusted or unadjusted models.   
 These analyses were repeated using quintiles of folate and B-6 from food only.  
No associations existed between both dementia and AD.  Similarly, no associations were 
observed in models with supplemental folate and B-6.   
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TABLE 3.4  
Nutrient intake by quintiles of folate intake from food1 
  Quintiles 
  1 2 3 4 5 
  (n=727) (n=727) (n=727) (n=727) (n=726) 
Total Folate intake (µg/d)1 185 ± 56 258 ± 13 302 ± 13 354 ± 19 506 ± 157*** 
Total Energy intake (kcal/d) 1910 ± 764 1963 ± 820 1967 ± 820 1963 ± 778 1966 ± 779 
Total Fat intake (g/d)1 69.9 ± 14.1 69.7 ± 14.0 69.7 ± 14.7 69.8 ± 14.2 70.4 ± 13.8 
Total Protein intake (g/d)1 87.3 ± 17.3 86.9 ± 18.5 87.0 ± 17.8 87.5 ± 18.8 86.2 ± 19 
Total CHO intake (g/d)1 265 ± 38.5 266 ± 41.2 265 ± 44.2 264 ± 39.0 266 ± 38 
Total Fiber intake (g/d)1 19.6 ± 7.0 19.9 ± 7.3 19.8 ± 7.8 19.8 ± 6.8 19.8 ± 6.8 
Total Vit C intake (mg/d)1 328 ± 328 338 ± 356 342 ± 361 342 ± 335 335 ± 345 
Total Iron Intake (mg/d)1 25.1 ± 34.3 24.6 ± 34.2 25.0 ± 38.0 27.6 ± 41.8 24.9 ± 34.6 
Total Vit B-12 (µg/d)1 6.2 ± 4.2 5.9 ± 3.3 6.3 ± 4.5 6.3 ± 4.4 6.2 ± 5.0 
Total Vit B-6 (mg/d)1 2.2 ± 0.7 2.2 ± 0.7 2.2 ± 0.7 2.3 ± 0.9 2.2 ± 0.6 
Servings of Fruit/day 2.9 ± 1.4 3.0 ± 1.4 3.0 ± 1.4 3.1 ± 1.4 3.0 ± 1.4 
Servings of Vegetables (no 
potato)/day 3.0 ± 1.5 3.1 ± 1.4 3.0 ± 1.4 3.0 ± 1.4 3.0 ± 1.4 
Servings of Dairy/day 2.2 ± 1.5 2.3 ± 1.5 2.2 ± 1.6 2.3 ± 1.6 2.1 ± 1.4 
Servings of Fish/day 0.2 ± 0.2 0.2 ± 0.2 0.2 ± 0.2 0.2 ± 0.2 0.2 ± 0.2 
Servings of Grain/day 3.1 ± 1.7 3.1 ± 1.7 3.1 ± 1.7 3.1 ± 1.7 3.1 ± 1.7 
Servings of Sweets/day 0.9 ± 1.1 0.9 ± 1.0 0.9 ± 1.0 0.9 ± 0.9 1.0 ± 1.2 
Servings of Meat & 
Poultry/day 1.0 ± 0.7 1.0 ± 0.6 1.0 ± 0.7 1.0 ± 0.8 1.0 ± 0.6 
MVM supp users (%) 40.8 42.5 43.1 44.5 42.7 
Folic acid supp users (%) 3.3 4.6 4.3 4.9 4.8 
B-Complex supp users (%) 10.3 10.3 10.1 11.7 11.2 
Vitamin B-6 supp users (%) 8.6 8.5 7.4 8.2 8.0 
1Energy adjusted nutrients from food sources only 
2
 ± SD (all such values). 
*p<0.05 for difference across quintiles 
**<0.01 for difference across quintiles 
***p<0.001 for difference across quintiles 
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TABLE 3.5  
Hazard ratios (95% CIs) for quintiles of total folate, vitamin B-12, and vitamin B-6 intake 
over 9 years of dementia or AD incidence  
Quintiles of Total Folate Intake 
 1 2 3 4 5 p-trend 
Dementia       
  Model 1 Ref 0.91 (0.64, 1.29) 0.88 (0.63, 1.25) 0.83 (0.58, 1.19) 1.07 (0.74, 1.54) 0.85 
  Model 2 Ref 0.89 (0.63, 1.25) 0.86 (0.61, 1.22) 0.80 (0.56, 1.15) 1.04 (0.75, 1.45) 0.89 
  Model 3 Ref 0.88 (0.62, 1.28) 0.89 (0.61, 1.28) 0.76 (0.51, 1.12) 1.08 (0.76, 1.55) 0.81 
AD       
  Model 1 Ref 1.08 (0.71, 1.66) 1.06 (0.69, 1.63) 0.84 (0.53, 1.33) 0.99 (0.64, 1.52) 0.60 
  Model 2 Ref 1.04 (0.68, 1.60) 1.02 (0.67, 1.56) 0.79 (0.50, 1.25) 0.93 (0.60, 1.44) 0.45 
  Model 3 Ref 1.04 (0.66, 1.63) 1.03 (0.66, 1.62) 0.75 (0.45, 1.23) 0.97 (0.61, 1.54) 0.53 
Quintiles of Total B-12 Intake 
 1 2 3 4 5 p-trend 
Dementia       
  Model 1 Ref 1.18 (0.82, 1.69) 1.44 (1.03, 2.01) 1.04 (0.67, 1.40) 1.13 (0.80, 1.62) 0.85 
  Model 2 Ref 1.18 (0.82, 1.69) 1.42 (1.02, 1.99) 0.95 (0.65. 1.37) 1.13 (0.79, 1.61) 0.92 
  Model 3 Ref 1.16 (0.79, 1.70) 1.33 (0.93, 1.92) 0.93 (0.60, 1.42) 1.03 (0.68, 1.56) 0.87 
AD       
  Model 1 Ref 1.06 (0.67, 1.68) 1.51 (1.00, 2.29) 0.96 (0.60, 1.52) 1.12 (.073, 1.73) 0.80 
  Model 2 Ref 1.05 (0.66, 1.67) 1.48 (0.98, 2.24) 0.92 (0.58, 1.46) 1.08 (0.69, 1.68) 0.96 
  Model 3 Ref 1.12 (0.69, 1.83) 1.47 (0.94, 2.31) 1.00 (0.58, 1.70) 1.03 (0.62, 1.73) 0.97 
Quintiles of Total B-6 Intake 
 1 2 3 4 5 p-trend 
Dementia       
  Model 1 Ref 0.94 (0.66, 1.34) 1.01 (0.72, 1.42) 0.99 (0.69, 1.40) 0.92 (0.64, 1.30) 0.75 
  Model 2 Ref 1.10 (1.57, 0.77) 1.03 (1.48, 0.72) 1.10 (1.55, 0.78) 1.06 (1.51, 0.75) 0.69 
  Model 3 Ref 1.03 (0.71, 1.51) 0.96 (0.66, 1.40) 0.94 (0.61, 1.45) 0.93 (0.59, 1.46) 0.98 
AD       
  Model 1 Ref 1.23 (0.53, 1.26) 1.20 (0.55, 1.28) 1.08 (0.60, 1.41) 1.22 (0.53, 1.27) 0.58 
  Model 2 Ref 1.27 (0.82, 1.97) 1.02 (0.65, 1.60) 1.03 (0.66, 1.60) 1.10 (0.71, 1.71) 0.42 
  Model 3 Ref 0.85 (0.54, 1.35) 0.74 (0.46, 1.19) 0.92 (0.55, 1.56) 0.82 (0.47, 1.43) 0.49 
Model 1- unadjusted  
Model 2- adjusted for gender, education  
Model 3- fully adjusted for gender, education, bmi (cont), total kcals (cont), physical activity, apoe, alcohol, smoking, 
MI, stroke, DM, and other B-vitamins scored in quintiles and treated as a continuous variables (18 = df). 
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TABLE 3.6  
Hazard ratios (95% CIs) for quintiles of food folate and vitamin B-6 intake over 9 years 
of dementia or AD incidence  
Quintiles of Food Folate Intake 
 1 2 3 4 5 p-trend 
Dementia  
     
  Model 1 Ref 0.95 (0.65, 1.40) 1.08 (0.75, 1.57) 1.23 (0.86, 1.76) 0.86 (0.58, 1.26) 0.93 
  Model 2 Ref 1.00 (0.70, 1.43) 1.00 (0.71, 1.43) 1.22 (0.87, 1.70) 0.86 (0.60, 1.24) 0.84 
  Model 3 Ref 0.99 (0.67, 1.45) 1.05 (0.72, 1.52) 1.27 (0.89, 1.82) 0.88 (0.60, 1.29) 0.97 
AD  
     
  Model 1 Ref 1.17 (0.73, 1.87) 1.12 (0.70, 1.79) 1.45 (0.93, 2.26) 1.54 (1.00, 2.38) 0.94 
  Model 2 Ref 0.96 (0.06, 1.53) 1.20 (0.78, 1.85) 1.28 (0.83, 1.97) 0.84 (0.52, 1.34) 0.95 
  Model 3 Ref 0.96 (0.58, 1.60) 1.27 (0.80, 2.01) 1.35 (0.86, 2.14) 0.91 (0.56, 1.50) 0.77 
Quintiles of Food B-6 Intake 
 1 2 3 4 5 p-trend 
Dementia  
     
  Model 1 Ref 0.91 (0.63, 1.33) 1.04 (0.73, 1.48) 0.78 (0.53, 1.14) 0.92 (0.65, 1.31) 0.53 
  Model 2 Ref 1.12 (0.80, 1.57) 1.00 (0.70, 1.43) 1.13 (0.81, 1.59) 0.94 (0.66, 1.34) 0.46 
  Model 3 Ref 1.23 (0.85, 1.78) 1.10 (0.75, 1.61) 1.37 (0.96, 1.97) 1.01 (0.70, 1.48) 0.22 
AD  
     
  Model 1 Ref 0.95 (0.60, 1.52) 1.24 (0.80, 1.92) 1.32 (0.86, 2.02) 0.85 (0.53, 1.37) 0.97 
  Model 2 Ref 0.76 (0.48, 1.21) 1.05 (0.70, 1.59) 0.69 (0.44, 1.09) 0.96 (0.64, 1.44) 0.75 
  Model 3 Ref 0.81 (0.49, 1.34) 1.21 (0.77, 1.90) 0.72 (0.44, 1.18) 0.89 (0.56, 1.40) 0.48 
Model 1- unadjusted 
Model 2- adjusted for gender, education 
Model 3- fully adjusted for gender, education, bmi (cont), total kcals (cont), physical activity, apoe, alcohol, smoking, 
MI, stroke, DM, and other B-vitamins scored in quintiles and treated as a continuous variables (18 = df). 
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TABLE 3.7  
Hazard ratios (95% CIs) for supplemental folate and vitamin B-6 intake over 9 years of 
dementia or AD incidence  
Supplemental Folate Intake* 
 1 2 p-trend 
Dementia  
  
  Model 1 Ref 1.08 (0.85, 1.37) 0.69 
  Model 2 Ref 1.03(0.82, 1.29) 0.78 
  Model 3 Ref 1.04 (0.81, 1.33) 0.76 
AD  
  
  Model 1 Ref 0.96 (0.72, 1.27) 0.74 
  Model 2 Ref 0.93 (0.69, 1.23) 0.39 
  Model 3 Ref 0.90 (0.66, 1.23) 0.52 
Supplemental B-6 Intake** 
 1 2 p-trend 
Dementia  
  
  Model 1 Ref 1.00 (0.79, 1.26) 0.77 
  Model 2 Ref 1.03 (0.82, 1.29) 0.73 
  Model 3 Ref 1.06 (0.77, 1.47) 0.72 
AD  
  
  Model 1 Ref 0.92 (0.70, 1.22) 0.83 
  Model 2 Ref 0.96 (0.60, 1.53) 0.79 
  Model 3 Ref 0.99 (0.66, 1.50) 0.96 
*Defined by supplemental intake of folic acid 1= <400µg/d, 2= >/= 400µg/d 
**Defined by supplemental intake of B-6 1= <2mg, 2 >2mg 
Model 1- unadjusted 
Model 2- adjusted for gender, education 
Model 3- fully adjusted for gender, education, bmi (cont), total kcals (cont), physical activity, apoe, alcohol, smoking, 
MI, stroke, DM, and other B-vitamins scored in quintiles and treated as a continuous variables (14 = df). 
 
 
 
 
DISCUSSION 
 Usual dietary intake of folate, vitamin B-12, and vitamin B-6 was not associated 
with risk for incident dementia or AD over 9 years among CCMS elders.  In models with 
the b-vitamins together, no association was found.  Neither folic acid nor B-6 from food 
or supplement intake was related to incident dementia and AD.  Vitamin B-12 from 
supplements was not analyzed, as oral B-12 supplementation is often given in high doses 
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(~1000 µg) in response to B-12 deficiency and actual absorbency varies in response to 
the degree of malabsorption.   
 Plausible biological mechanisms link folate and other B-vitamins to AD, and 
originate from their roles in methylation reactions of one-carbon metabolism.  Deficiency 
of B-vitamins has been known to raise levels of homocysteine levels via disrupted one-
carbon metabolism (25).  It has been proposed that elevated levels of homocysteine may 
induce oxidative stress and increase damage to neurotoxicity (40-42).  Damaged or 
altered environment in the brain may contribute to increased plaques and tangles 
observed in persons with AD.  In addition to elevated homocysteine levels, other 
consequences of disturb one-carbon metabolism include decrease levels of S-adenosyl-
methionine (SAM), increased S-adenosylhomocysteine (SAH), limitation of certain folate 
metabolites (25, 43).  
 SAM is required for methylation reactions of DNA/RNA and neurotransmitters, 
specifically it functions affect proteins, membrane phospholipids, neurotransmitters, and 
DNA structure.  In adequate levels of SAM may alter normal brain functions or damage 
vital structures for normal cognitive function (25, 43).  SAH the precursor to 
homocysteine, has also been observed at irregular levels in individuals with AD similar to 
homocysteine, SAM and B-vitamins like folate, B-12, and B-6 (44).  It is thought to 
increase as homocysteine metabolism is inhibited.  SAH is an intermediate between SAM 
and homocysteine.  One study noted that increases in SAH inhibited normal functions of 
SAM  in the brain (6).   
 Vitamin B-12 is a cofactor for methionine synthase, the enzyme that transfers a 
methyl group from 5-methyl-THF to homocysteine to form methionine.  The conversion 
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of 5,10 methylene-THF to 5-methyl-THF requires the enzyme, methyltetrahydrofolate 
reductase.  This reaction is irreversible, therefore deficiency of B-12, prevents 5-methyl-
THF from being converted forward to other folate forms or back to 5,10 methylene-THF.  
Lack of these other essential cofactor forms of folate may cause breaks in DNA, which 
may influence damage common in AD patients brains (43). 
 Homocysteine can be metabolized via two different pathways, the previously 
mentioned reaction requiring 5-methyl-THF and B-12 and an althernative pathway which 
requires B-6 as a cofactor in converting homocysteine to cystathioine.  Further, 
downstream of this pathway glutathione is produced, a key antioxidant for preventing 
lipid peroxidation and other oxidative damage.  Therefore, disrupted brain function may 
also be related to the decreased production of glutathione via metabolism of 
homocysteine to cystathione.  
Prevalence of B-vitamin deficiencies, especially B-12, are higher among elderly 
populations.  Conditions which inhibit vitamin B-12 absorption such as gastritis have 
been estimated to affect 20-50% of the elderly in the US.  Among the Framingham group    
24% of elders age 60-69 and 37% of those older than 80 were found to have gastritis 
depending upon diagnosis criteria followed (6).  Deficiency of folate is also suspected to 
be higher among elderly groups and may increase with age due to decreased absorption 
caused by changes in the gastrointestinal tract even studies examining folate intake post-
fortification have also seen average intakes below recommendations (26, 45). 
In 1998, a mandate requiring all cereal grains to be fortified with folic acid was 
instated in response to research on folate status and neural tube defects in pregnant 
women.  Standardized levels of 140 µg per 100 grams of grain was required (46).  Some 
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have raised concern that the benefits may not reach all populations and may even be 
detrimental to subgroups (33, 47).  Mechanistically, concern is derived from the concept 
that high levels of folic acid may “mask” evidence of vitamin B-12 deficiency (30, 31).  
Macrocytic anemia is a common consequence of deficiency of either B-12 or folate.  
Clinically, supplementation with folic acid is often the treatment prescribed for 
macrocytic anemia, such treatment strategies may alleviates symptoms of anemia while 
further camouflaging B-12 deficiencies.  Prolonged B-12 deficiency has been seen to 
cause cognitive deficits and in certain cases, depending upon severity and duration of the 
deficiency, has been irreversible (26).   
Since the time of mandatory folate fortification, increases in serum levels of folate 
have been observed indicating that though many products were already fortified with 
folic acid, the mandate did meet its goal of increasing average intakes of folic acid.  The 
Framingham group observed a 38% increase of serum RBC folate among participants 
who did not consume supplements post-fortification; they also estimated a 3% less of 
there cohort were deficient in folate post-fortification compared to pre-fortification (30).  
As the top contributor to folate, RTEC has been studied since the fortification of cereal 
grains with folic acid.  Findings which suggest vitamins fortified in foods like RTEC may 
be more bioavailable than naturally occurring sources of folate (48).   If folate was 
independently associated to increased risk for cognitive decline and AD, a decrease or 
slow in incidence would have been expected.  No such report or observation has been 
made.  One study, by Morris et al. (47) did report increased risk for anemia and cognitive 
decline among those with low serum B-12 and high serum folate.  The study included 
1459 senior participants in the 1999-2002 US National Health and Nutrition Examination 
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Survey.  Morris et al. (33) also found high folate intake to be associated with faster 
cognitive decline among a group of elderly from the Chicago Health and Aging Project.  
These finding support concerns that high folate may be toxic in certain situations. 
It appears that dietary folate is not a marker of a dietary pattern and is somewhat 
ubiquitously distributed in a wide variety of foods since the fortification of the US food 
supply with folic acid.  In 1995, the CCMS participants averaged intake of folate from 
food was below the RDA (400 µg/d) at 319 µg/d and 46.9 % received less than the RDA 
including folate from supplements and 77.1% received less than the RDA from food 
folate.  This data was collected pre-folate fortification and higher intakes could be 
expected in most participants post-fortification.  It should also be noted that dietary intake 
was collected using FFQ’s; FFQ’s are better at detecting relative intake comparing 
individuals and lack the ability to assess actual intake.  An analysis of participants with 
low serum levels and inadequate dietary intake of B-vitamins may offer more insight to 
mediating effects of B-vitamins at different levels of intake.  Associations between 
dietary intake and AD may be difficult to detect as dietary intake in elderly may not 
indicate actual nutriture.  Increases in malabsorption related to gastritis or pernicious 
anemia contribute to the problem of using dietary data alone to assess possible 
associations between B-vitamins and AD. 
It is not surprising that results from population-based prospective studies on B-
vitamins and cognitive health vary significantly.  The studies range in examining 
combinations of B-vitamins from food, supplements, total, related biomarkers and 
outcome variables of cognitive decline, incident dementia, and incident AD.  
Additionally methods of analyzing dietary intake, nutriture, cognition, and type of 
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dementia have been inconsistent.  Results from this study appear consistent with some 
(34) but not all recently published data (5, 49) similar in design.  There is little 
information on dietary intake of B-vitamins and AD (5, 34, 49).  Corrado et al. (50) 
published an analysis that found no independent relation between total B-12 with incident 
of AD in the Baltimore Longitudinal Study of Aging (BLSA).  The BLSA is a population 
based cohort study of elderly men and women from the Baltimore area.  Higher folate 
was associated with decreased risk for incident AD (RR: 0.45; 95% CI: 0.2, 0.97) in an 
adjusted model with age, gender, education, and caloric intake.  Participants in the BLSA 
had similar methods to the CCMS with the use of proportional hazards modeling over an 
average of 9.3 years, similar to follow-up time in Cache participants.  At baseline 
subjects in the BLSA were somewhat younger than CCMS participants (5). 
Morris and colleagues conducted longitudinal assessment of incident AD across 
folate consumption from the Chicago Health and Aging Project (CHAP) (34).   Of 1041 
participants of the CHAP study, 162 developed incident AD, and similar to the results 
presented here, quintiles of B-vitamin intake from food and food and supplement were 
not associated with incidence of AD.  Average intake of total folate in the CHAP was 
similar to the CCMS (CHAP: 338 µg/d and CCMS: 319 µg/d).  Most of the CHAP 
dietary data was also collected pre-fortification (86%).   Morris et al. had an average of 
3.9 years of follow-up and used logistic regression to analyze odds between quintiles of 
B-vitamins and incidence of AD; the use of logistic regression does not account for 
censored cases in the analysis (34).   
The Washington Heights Inwood Columbia Aging Project involved a smaller 
group (n=965) than the CCMS (49).  They reported the highest quartile of folate (food 
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plus supplement) intake (>489.7 µg) (equivalent to quintile four in the CCMS) was 
related to a decrease risk for AD (HR: 0.5; 95% CI: 0.3, 0.9).  Of 965 participants, 192 
develop AD after 6 years; this is a much higher rate of incidence compared to the CCMS 
(49).   
Among studies that explored serum biomarkers and incident dementia/AD results 
also vary.  Among studies that examined homocysteine two out of three found elevated 
homocysteine to be related to incident AD (18, 51, 52).  Wang et al. (53) examined serum 
folate and B-12 in relation to incident AD and found nearly double the risk for AD 
among subjects deficient in folate or B-12.  The Conselice Study of Brain Aging (CSBA) 
also found low serum folate to be related to increased risk for AD (5).   
The Cache Study has many strengths including a large homogenous population, 
lengthy follow-up time, high rates of participation and retention, a diverse and 
inconclusive data set of demographic information, medical history, medication usage, 
cognitive assessment, dietary intake, lifestyle and environment information (occupational 
history), etc.  Limitations to this study include limitations of using a FFQ for diet 
assessment, a lack of associated vitamin biomarkers, and usual limitations associated 
with participants who drop out or are lost to follow-up.  Limitations of FFQs include their 
ability to only detect dietary patterns and not actual intakes.  Knowledge of actual 
nutriture via serum markers to evaluate differences in reported dietary intake and B-
vitamin status would allow for better understanding of how B-vitamins may be associated 
with dementia and AD.   FFQs are good tools for analyzing average dietary intakes over 
longer periods of time than 24-hour recalls or diet record, but generally are not known for 
detecting actual intake, as they are best designed to detect frequency.   Our study’s FFQ 
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was modeled after that of the Nurse’s Health Study which has reported significant 
correlations between their FFQ estimates of dietary intake and estimates from dietary 
records collected in validation studies (35, 36).   Data distinguishing between participants 
using B-12 supplementation or injections in response to malabsorption problems or for 
other purposes was not available for this analysis.   
Use of the Cox Proportional Hazards statistical method is designed to help 
account for bias coming from censored cases like those who die prior to developing AD 
or those who are lost to follow-up.  Logistic regression cannot account for participants 
who are lost to follow-up or die prior to developing dementia or AD.  Several other 
studies examining incident AD use Cox modeling (5, 49), only one did not (34). 
Several studies have looked at correlations between dietary intake and biomarkers 
of B-vitamin status.  In the Framingham cohort an association between increasing intake 
of good food folate sources like breakfast cereal and fruit and vegetables was made with 
increased plasma folate and decreased serum homocysteine (54).  Trials using un-
fortified and fortified ready-to-eat breakfast cereals also saw increased serum levels of B-
vitamins with increased dietary intake (55).  The trial involved 215 generally healthy and 
disease-free elders who did not use supplements (55).   
Cache populations are an interesting group to study cognitive health in because 
they are an unusually long lived.  The 1990, US census identified Cache County as the 
longest lived county.  Males from Cache County were estimated to live almost 10 years 
longer than the national average for male life expectancy.  Another strength is that the 
participation rate was extremely high, nearly 90% at baseline and 79% during the last 
wave of data collection after three examinations and 9 years of follow-ups.  The majority 
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of the population is white, members of The Church of Jesus Christ of Latter Day 
Saints, and consequently low rates of alcohol and tobacco use.  Participants also have 
about an 80% rate of having at least a high school education.  They are known for low 
rates of migration and for their tight knit families and community.  The CCMS has a 
longer follow-up time than most studies similar in design and hypothesis.  Detailed 
clinical assessment was used to assign diagnosis.  All of these factors are benefits for 
longitudinal study designs. 
Studies that include examining dietary B-vitamins, associated serum biomarkers, 
and incident dementia/AD with adequate power and follow-up time would be valuable to 
clarifying relationships.  No studies with this design to date have been published.   
 
CONCLUSIONS 
 In summary we did not find folate from food, supplements, or from combined 
sources to be independently associated with incident dementia or AD.  Average intake of 
folate from food in 1995, pre-folate fortification mandate, was seen to be less than dietary 
recommended intakes; although average intake of folate from food and supplement 
combined exceeded the DRI.  Further studies should be done using serum biomarkers to 
assess the influence and possible interactions of B-vitamin status in relation to incident 
dementia and AD.  Some randomized trials have shown improvement of cognitive health 
with increased B-vitamin intake among subjects who are deficient (5, 56).  Results from 
this study do not support the routine use of B-vitamin supplements in effort to reduce risk 
of dementia in general populations.   
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      CHAPTER 4 
CONCLUSIONS 
 
 
Total folate, B-12, and B-6 intake among men and women from the CCMS was 
not related to incidence of dementia or AD.  Results from this study are not consistent 
with hypotheses that higher B-vitamin intake may prevent cognitive impairment and 
ultimately AD.   
However, it is important to note that dietary intake may not adequately reflect B-
vitamin status as elderly have higher rates of B-vitamin malabsorption and deficiency (1).  
Elderly have high rates of conditions like gastritis known to inhibit absorption of B-
vitamins.   In the Framingham cohort an estimated 24-37% of elderly participants may 
have had gastritis depending upon diagnosis criteria used (2).  Conditions like pernicious 
anemia, use of acid blockers, and other medications also increase malabsorption of B-12 
among elderly (3).  Serum status may also be related to genetic variation and 
polymorphisms of important enzymes involved in one-carbon metabolism (4).  
Interactions among B-vitamins and status of other nutrients involved in methylation, not 
previously discussed, such as zinc, choline, and riboflavin may also affect status and 
normal functioning of one-carbon metabolism (5, 6). 
Folate deficiency is less common since the fortification of the US food supply 
with folic acid (7).  The average intake among CCMS participants of folate from food 
was below recommendations of 400 µg/d at an average of 319 µg/d pre-fortification.  Of 
the CCMS, 46.9 % received less than the RDA including folate from supplements and 
77.1% received less than the RDA from food folate alone.   This may be concerning since 
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elderly populations have higher rates of B-vitamin malabsorption and may require 
higher intakes.   
 Studies examining B-vitamins and incidence of dementia and AD have varying 
results (8-10).  Luchsinger et al. (9) found increased intake of folate was related to 
decreased risk for incident AD in a group of elderly.  In the CHAP study, dietary and 
total B-vitamin intake was not associated with incident AD (10).  And Corrado et al. (11) 
found folate and B-6 to be independently related to incidence of AD; B-12 was not 
related and in adjusted models higher folate intake was the only vitamin related to lower 
risk for AD.    
Some studies involving subjects with prevalent B-vitamin deficiencies have seen 
benefits with increasing intake (8).  The degree of deficiency was usually related to the 
amount of improvement with supplementation.  Supplemental trials have also seen 
divided results with four of seven trials reported results (8, 12-14) and three of seven 
results no reported no associations (8, 14, 15).  In the studies that did not see cognitive 
improvements decrease in homocysteine was observed, which supports some theories 
that homocysteine is a marker of cognitive impairment not a risk factor (8). 
 Folate fortification of the food supply is a concern among elderly, as it may mask 
a vitamin B-12 deficiency (16).  Vitamin B-12 also plays a role independent of one-
carbon metabolism as a cofactor in the reaction of methylmalonic acid to succinyl-CoA.  
Prolonged deficiency of B-12 may cause irreversible dementia, which may be related to 
B-12’s role in methylmalonic acids conversion to succinyl-CoA (17).  High intake of 
folate or supplementation with folic acid alleviates the most obvious symptom of B-12 
deficiency, anemia, while the underlying B-12 deficiency is left untreated (16).  Morris et 
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al. (18) observed serum levels of low B-12 and high folate to be related to increased 
risk for cognitive impairment.  Some discussion on whether the food supply should also 
be fortified with B-12 has been published, most experts agree more research is needed 
before an informed decision can be made (19).  Dietary data taken at baseline in the 
CCMS is pre-fortification mandate dietary data.  The CCMS also collected dietary data at 
wave three, which occurred post-fortification (2002-2004).  Comparison of these two 
waves of data would be an important and valuable to answer the questions surrounding 
folic acid, B-12 and other B-vitamin interactions.   
Increased intake of B-vitamin-dense foods like fruits, vegetables, low-fat dairy 
and whole grains would be beneficial because of other benefits including decreased heart 
disease, increased weight loss/control, etc. which is associated with intake of these foods 
for general health, despite the lack of possible benefits in cognition.  Further investigation 
on this topic is warranted.  Large prospective studies that examine dietary, supplemental, 
serum biomarkers of B-vitamins and genotypes of relevant enzymes involved in one-
carbon metabolism and other reactions requiring B-vitamins may concurrently be able to 
detect possible associations between intake/status and cognitive health.   
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APPENDIX. Wave 1 food frequency questionnaire 
 
 
 
 
 
 
CACHE COUNTY STUDY ON MEMORY IN AGING 
NUTRITION QUESTIONNAIRE 
Conducted by:  Utah State University 
Marking Instructions 
 
Please follow these few simple rules in completing this questionnaire. 
1. Use only a pencil.  (Please DO NOT use a pen) 
2. Darken completely the circle of the answer you choose 
3. Erase cleanly any answer that you wish to change 
4. Make no stray marks of any kind on the form 
5. For food that you never or rarely eat, please mark the first column 
labeled “None or  
 Less than once a month.  Please do not leave any food items blank. 
6. Please note the correct way to mark the answers. 
 Correct Mark Incorrect Mark   
           
Please answer the following.  Check the appropriate gender, and fill in your 
height, weight, and age 
Male_____ Female_____  
Height_____ Weight_____ Age_____ 
THANK YOU!!!! 
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DIETARY SUPPLEMENTS 
 
 
 
PLEASE INDICATE WHICH, IF ANY, OF THE FOLLOWING SUPPLEMENTS YOU ARE 
CURRENTLY TAKING.  PLEASE ANSWER “YES” OR “NO” FOR ANY SUPPLEMENT 
LISTED. 
 
 
 
1. 
 
 
Do you regularly take multivitamins 
 
 NO> PLEASE GO TO QUESTION 2 
 
YES> CONTINUE: 
 
 (A) How many years have you taken multivitamins? 
 
   0-1 years   5-9 years 
 
   2-4 years   10 or more years 
 
 (B) What specific brand do you use?__________________________ 
 
Excluding multivitamins, do you take any of the following supplements listed 
below? 
 
2. 
 
 
Do you regularly take Vitamin A? 
 
 NO> PLEASE GO TO QUESTION 3 
 
 YES> CONTINUE: 
 
 (A) How many years have you taken multivitamins? 
 
   0-1 years   5-9 years 
 
   2-4 years   10 or more years 
 
 (B) What dose do you take per day? 
 
   less than 8,000 IU   22,001 IU or more 
 
  8,001 to 13,000 IU  Don’t know 
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   13,001 to 22,000 IU 
3. 
 
 
Do you regularly take Vitamin C? 
 NO> PLEASE GO TO QUESTION 4 
 
YES> CONTINUE: 
 
 (A) How many years have you taken multivitamins? 
 
   0-1 years   5-9 years 
 
   2-4 years   10 or more years 
 
 (B) What dose do you take per day? 
 
   less than 400 mg   1301 mg or more 
 
   401 to 700 mg  Don’t know 
 
   701 to 1300 mg 
 
4. 
 
 
Do you regularly take Vitamin C? 
 
 NO> PLEASE GO TO QUESTION 5 
 
 YES> CONTINUE: 
 
 (A) How many years have you taken multivitamins? 
 
   0-1 years   5-9 years 
 
   2-4 years   10 or more years 
 
 (B) What dose do you take per day? 
 
   less than 100IU   504 IU or more 
 
   101 to 300 IU  Don’t know 
 
   301 to 500 IU 
  
103 
 
 
5. 
 
 
Do you regularly take Calcium? 
 
 NO> PLEASE GO TO QUESTION 6 
 
 YES> CONTINUE: 
 
 (A) How many years have you taken multivitamins? 
 
   0-1 years   5-9 years 
 
   2-4 years   10 or more years 
 
 (B) What dose do you take per day? 
 
   less than 400 mg   1301 mg or more 
 
   401 to 900 mg  Don’t know 
 
   901 to 1300 mg 
 
6. 
 
Do you regularly take Vitamin D? 
 
 NO> PLEASE GO TO QUESTION 7 
 
 YES> CONTINUE: 
 
 (A) How many years have you taken multivitamins? 
 
   0-1 years   5-9 years 
 
   2-4 years   10 or more years 
 
 (B) What dose do you take per day? 
 
   less than 200 IU   1,000 IU or more 
 
   201 to 400 IU                 Don’t know 
 
   401 to 1,000 IU 
 
7. 
 
 
Do you regularly take Vitamin B6? 
 
 NO> PLEASE GO TO QUESTION 8 
 
  
104 
 
 YES> CONTINUE: 
 
 (A) How many years have you taken multivitamins? 
 
   0-1 years   5-9 years 
 
   2-4 years   10 or more years 
 
 (B) What dose do you take per day? 
 
   less than 10 mg   80 mg or more 
 
   10 to 39 mg   Don’t know 
 
   40 to 79 mg 
 
8. 
 
 
Do you regularly take Selenium? 
 
 NO> PLEASE GO TO QUESTION 9 
 
 YES> CONTINUE: 
 
 (A) How many years have you taken multivitamins? 
 
   0-1 years   5-9 years 
 
   2-4 years   10 or more years 
 
 (B) What dose do you take per day? 
 
   less than 80 mcg   251 mcg or more 
 
   81 to 130 mcg  Don’t know 
 
   131 to 250 mcg 
 
FOR OFFICE USE ONLY 
A          B          C          
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 
                              
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 
                              
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9. 
 
 
Do you regularly take Iron? 
 
NO> PLEASE GO TO QUESTION 10 
 
YES> CONTINUE: 
 
 (A) How many years have you taken multivitamins? 
 
   0-1 years   5-9 years 
 
   2-4 years   10 or more years 
 
 (B) What dose do you take per day? 
 
   50 mg or less    401 mg or more 
 
   51 to 200 mg   Don’t know 
 
   201 to 400 mg 
 
10. 
 
 
Do you regularly take Zinc? 
 
 NO> PLEASE GO TO NEXT SECTION 
 
YES> CONTINUE: 
 
 (A) How many years have you taken multivitamins? 
 
   0-1 years   5-9 years 
 
   2-4 years   10 or more years 
 
 (B) What dose do you take per day? 
 
   less than 25 mg   101 mg or more 
 
   26 to 75 mg   Don’t know 
 
   76 to 100 mg 
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11. DO YOU TAKE ANY OF THE FOLLOWING OTHER SUPPLEMENTS: 
 
Cod liver oil........... Yes ......... No Folic acid .............. Yes ......... No 
 
Other fish oil .......... Yes ......... No Iodine .................... Yes ......... No 
 
Niacin .................... Yes ......... No Brewer’s Yeast ...... Yes ......... No 
 
Beta-caroten........ Yes ......... No Magnesium........... Yes ......... No 
 
Thiamine (vitamin B1).... Yes ... No Any others?........... Yes ......... No 
 
B-complex vitamins ....... Yes ... No If yes, please 
specify_____________________ 
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FOODS YOU EAT 
 
AVERAGE USE FOR PAST 12 MONTHS 
For each food listed, please 
mark a circle for how often 
during the past year, on 
average, you have eaten the 
serving size specified.  Be 
sure to mark a circle for 
every food listed.  If you 
never eat the food listed 
mark the circle in the first 
column. 
 
DAIRY FOODS 
NON
E  
OR  
LESS  
THA
N  
1  
PER  
MO. 
1-3 
PER 
M
O. 
1 
PE
R 
WK
. 
2-4 
PE
R 
WK
. 
5-6 
PE
R 
WK
. 
1 
PE
R 
DA
Y 
2-3 
PE
R 
DA
Y 
4-5 
PE
R 
DA
Y 
6  
PE
R 
DA
Y 
Skim or low fat milk (8 oz. 
glass) 
 
         
Whole milk (8 oz. glass) 
 
         
Chocolate milk or cocoa (8 
oz. glass) 
 
         
Cream or half-and-half, e.g. 
coffee, whipped (Tbs) 
 
         
Sour cream (Tbs) 
 
         
Non-dairy coffee whitener 
(tsp) 
         
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Sherbet, ice milk, or frozen 
yogurt (1/2 cup) 
 
         
Ice cream (1/2 cup)          
Yogurt (1 cup) 
 
         
Cottage or ricotta cheese 
(1/2 cup) 
 
         
Cream cheese (1 oz.) 
 
         
Other cheese, e.g. 
American,  
cheddar, etc., plain or as 
part of a dish (1 slice or 1 oz. 
serving) 
 
         
Margarine (1 tsp, added to 
food or bread; exclude use 
in cooking 
 
         
Butter (1 tsp), added to food 
or bread; exclude use in 
cooking. 
 
         
FRUITS 
 
         
Raisins (1 oz. or small pack ) 
or grapes (1/2 c) 
 
         
Prunes (7 prunes or ½ cup) 
 
         
Bananas (1) 
 
         
  
109 
 
Cantaloupe (1/4 melon) 
 
         
Avocado (1/2 fruit or ½ cup) 
 
         
Fresh apples or pears (1) 
 
         
Apple juice or cider (small 
glass) 
 
         
Oranges (1) 
 
         
Orange Juice (small glass) 
 
         
Grapefruit (1/2) 
 
         
Grapefruit juice (small glass) 
 
         
Other fruit juices (small glass) 
 
         
Strawberries, fresh, frozen or  
canned (1/2 cup) 
 
         
Blueberries, fresh, frozen or  
canned (1/2 cup) 
 
         
Peaches, apricots or plums (1  
fresh, or ½ cup canned) 
 
         
VEGETABLES 
 
         
Tomatoes (1) 
 
         
Tomato juice, V8 (small glass) 
 
         
Tomato sauce (1/2 cup) e.g. 
spaghetti sauce 
 
         
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Salsa or red chili sauce (1 
Tbs) 
 
         
Tofu or soybeans (3-4 oz.) 
 
         
String (green) beans (1/2 
cup) 
 
         
Broccoli (1/2 cup) 
 
         
Cabbage or cole slaw (1/2 
cup) 
 
         
Cauliflower (1/2 cup) 
 
         
Brussels sprouts (1/2 cup)          
Carrots, raw (1/2 carrot or 4 
sticks) 
 
         
Carrots, cooked (1/2 cup) or 
carrot juice (2-3 oz.) 
 
         
Red Beets—not greens (1/2 
cup) 
 
         
Corn (1 ear or ½ cup frozen 
or canned) 
 
         
Peas or lima beans (1/2 cup 
fresh, frozen, or canned) 
 
         
Mixed vegetables (1/2 cup) 
 
         
Beans or lentils, baked or 
dried (1/2 cup) 
 
         
Dark orange (winter) squash 
(1/2 cup) (acorn, butternut 
squash) 
 
         
Eggplant, zucchini or other 
summer squash (1/2 cup) 
 
         
Yams or sweet potatoes (1/2 
cup) 
 
         
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Spinach, cooked (1/2 cup) 
 
         
Spinach, raw as in a salad (1 
cup serving) 
 
         
Kale, mustard or chard 
greens (1/2 cup) 
 
         
Iceberg or head lettuce (1 
cup serving) 
 
         
Romaine or leaf lettuce (1 
cup serving) 
 
         
Celery (2-4 4” sticks) 
 
         
Sweet green or red peppers 
(3 slices or ¼ pepper) 
 
 
         
Onions as a garnish, or in 
salad (1 slice) 
 
         
Onions as a vegetable, rings 
or in soup (1 onion) 
 
         
EGGS, MEATS, ETC. 
 
         
Eggs (1) 
 
         
Chicken with skin (4-6 oz.) 
 
         
Chicken without the skin (4-6 
oz.), includes grilled chicken 
sandwich 
 
         
Turkey, including ground 
turkey (4-6 oz. or 2 turkey 
dogs) 
 
         
Hot dogs 91) 
 
         
Bacon (2 slices) 
 
         
Processed meats, e.g. 
sausage, salami, bologna, 
         
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etc. (1 piece or slice) 
 
Hamburger (1 patty) 
 
         
Taco or tostado (1) 
 
         
Burrito (1) 
 
         
Enchilada (2) 
 
         
Beef, pork or lamb as a 
sandwich or mixed dish, e.g. 
stew, casserole, lasagna, chili 
etc. 
 
         
Pork as a main dish, e.g. ham 
or chops (4-6 oz.) 
 
         
Beef or lamb as a main dish, 
e.g. steak, roast (4-6 oz) 
 
         
Liver: beef, calf, or pork (4 oz) 
 
         
Liver: chicken or turkey (2 oz) 
 
         
Canned tuna fish (3-4 oz) 
 
         
Dark meat fish, e.g. 
mackerel, salmon, sardines, 
bluefish, swordfish (3-5 oz.) 
 
         
Fried fish, e.g. fish sticks, fish 
and chips style fish (3-5 oz.) 
 
         
Other fish (3-5 oz.) 
 
         
Shrimp, lobster, scallops as a 
main dish 
 
         
BREADS, CEREALS, STARCHES 
 
         
Cold breakfast cereal (1 
cup) 
 
         
Cooked oatmeal/cooked 
oat bran ( 1 cup) 
         
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Other cooked breakfast 
cereal (1 cup) 
 
         
Instant breakfast beverage, 
e.g. Carnation 
 
         
White bread (slice), including 
pita bread 
 
         
Dark bread (slice), including 
pita bread 
 
         
English muffins, bagels, or 
dinner rolls (1 each) 
         
Muffins or biscuits (1 each) 
 
         
White rice (1 cup) 
 
         
Pasta, e.g. spaghetti, 
noodles, etc (1 cup) 
 
         
Tortillas (1-10 inch shell) 
 
         
Other grains, e.g. bulgur, 
kasha, couscous, etc ( 1 cup) 
 
         
Pancakes or waffles (2 each) 
 
         
French fried potatoes (4 oz. 
or size of small fries order) 
 
         
Potatoes, baked, boiled 
(1each), or mashed (1 cup) 
 
         
Potato chips or corn chips 
(small bag or 1 oz.) 
 
         
Crackers, e.g. Triscuits, Wheat 
Things (5 each) 
 
         
Pizza (2 slices) 
 
         
BEVERAGES 
 
         
Plain water, bottled or tap (1          
  
114 
 
cup or 8 oz. glass) 
 
Hawaiian Punch, lemonade, 
or other non-carbonated fruit 
drinks ( 1 glass, bottle, can) 
 
         
Low-calorie cola, e.g. Diet 
Coke with caffeine (can) 
 
         
Low-calorie caffeine-free 
cola (can) 
 
         
Other low-calorie 
carbonated beverage, e.g. 
Fresca, Diet 7-UP (can) 
 
         
7-Up, diet ginger ale (can) 
 
         
Coke, Pepsi, or other cola 
with sugar (can) 
 
         
Caffeine Free Coke, Pepsi, or 
other cola with sugar (can) 
 
         
Other carbonated 
beverages with sugar, e.g. 
Sprite, Root beer (can) 
 
         
Regular Beer (1 glass, bottle, 
or can) 
 
         
Light Beer (1 glass, bottle, or 
can) 
 
         
Red wine (4 oz. glass) 
 
         
White Wine (4 oz. glass) 
 
         
Liquor, e.g. whiskey, gin, etc 
(1 drink or shot) 
 
         
Dark tea with caffeine (1 
cup), not herbal tea 
 
         
Green tea or herbal tea (1 
cup) 
         
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Coffee with caffeine (1 cup) 
 
         
Decaffeinated coffee (1 
cup) 
 
         
SWEETS, BAKED BGOODS, 
MISC 
 
         
Chocolate (bar or packet) 
e.g.  
 
Hershey’s M & M’s 
 
         
Candy bars, e.g. Snicker, 
milky  
 
way, Reeses 
 
         
Candy other than chocolate 
(1 oz) 
 
         
Cookies, home baked (1) 
 
         
Cookies, ready make (1) 
 
         
Brownies (1) 
 
         
Doughnuts (1) 
 
         
Cake, home baked (1 slice) 
 
         
Cake, ready make (1 slice) 
 
         
Pie, homemade ( 1 slice) 
 
         
Pie, ready made ( 1 slice) 
 
         
Sweet roll, coffee cake or 
other pastry, home baked (1 
each) 
 
         
Sweet roll, coffee cake or 
other pastry, ready made (1 
each) 
 
         
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Jams, jellies, preserves, syrup, 
or honey (1 Tbs) 
 
         
Peanut butter ( 1 Tbs) 
 
         
Popcorn (1 cup) 
 
         
Peanuts (small packet or 1 
oz.) 
 
         
Other nuts (small packet or 1 
oz.) 
 
         
Oat bran, added to food (1 
Tbs) 
 
         
Other bran, added to food 
(1Tbs) 
 
         
Wheat germ (1 Tbs) 
 
         
Chowder or cream soup (1 
cup) 
 
         
Olive oil salad dressing (1 Tbs) 
 
         
Other oil and vinegar 
dressing, e. g. Italian (1 Tbs) 
 
         
Mayonnaise or other creamy 
salad dressing ( 1 Tbs) 
 
         
Salt added at table (1 shake) 
 
         
Garlic (1 clove or 4 shakes) 
 
         
 
FOOD PREPARATION 
1. 
 
Do you eat cold breakfast cereal? 
 
 NO> PLEASE GO TO NEXT QUESTION 
 
 YES> What kind do you usually 
eat?______________________________________ 
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2. How many teaspoons of sugar do you add to your beverages or food each 
day? 
 
  0-1  2-4  5-9 10 or more 
 
3. When you have beef or lamb as a main dish, how is the meat cooked? 
 
 Rare    medium   well 
 
 Medium rare  medium well  do not eat meat 
 
4. How much of the visible fat on your beef, pork, or lamb do you remove 
before eating? 
 
 remove all visible fat   remove none 
 
 remove most visible fat do not eat meat 
 
 remove small part of visible fat 
 
5. How often do you eat food that is fried at home? (exclude Pam-type spray) 
 
 less than once per week   4-6 times per week 
 
 1-3 times per week    daily 
 
6. How often do you eat fried food away from home? (e.g. french fries, fried 
chicken, fried fish). 
 
 less than once per week   4-6 times per week 
 
 1-3 times per week    daily 
 
7. What type  and brand of cooking oil or fat do you usually use at home (e.g. 
corn oil, Mazola brand; lard) 
 
Type:_________________________________________________ 
 
Brand:________________________________________________ 
 
8. How does the amount of food you eat now compare to the amount you 
ate five years ago? 
 
 I eat almost the same 
 
 I eat less now 
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 I eat more now 
 
9. What was the main source of your drinking water over the past year? 
 
 city system 
 
 rural or county system 
 
 private well 
 
 bottled water 
 
 other (please specify______________________________________________) 
 
 
FOR OFFICE USE ONLY 
(
D
) 
         (
E
) 
         (
F
) 
         
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 
                             
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 
                             
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YOUR ACTIVITES 
1. About how many hours per day do you spend in light activity, such as 
walking, shopping, child care, cooking, carrying light objects, cleaning, 
and repairing? 
 
 
Hours per day_________ 
 
2. About how often do you take part in moderate physical activities including 
bowling, golf, light swimming, gardening, walks over 15 minutes, fishing, light 
bicycling, or other light sports. 
 
Usually every day 
 
 2-6 times a week 
 
 About once a week 
 
 A few times a month 
 
 A few times a year 
 
 Rarely or never 
 
3. About how often do you take part in vigorous physical activity including 
jobbing, tennis, racquetball or squash, lap swimming, aerobics, vigorous 
bicycling, skiing, hiking, hunting or other vigorous sports… 
 
Usually every day 
 
 2-6 times a week 
 
 About once a week 
 
 A few times a month 
 
 A few times a year 
 
 Rarely or never 
 
4. How often do you talk on the telephone with family, friends, or neighbors? 
 
Usually every day 
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 2-6 times a week 
 
 About once a week 
 
 A few times a month 
 
 A few times a year 
 
 Rarely or never 
 
5. How often do you get together with family, friends, or neighbors?  This 
includes meeting in your own home, meeting in other’s homes, or going out 
together. 
 
Usually every day 
 
 2-6 times a week 
 
 About once a week 
 
 A few times a month 
 
 A few times a year 
 
 Rarely or never 
 
6. How often do you attend meetings of social clubs, groups, or organizations 
such as bridge clubs, book clubs, hospital volunteer, gardening clubs, 
Rotary club, Kiwanis, VFW, etc. 
 
Usually every day 
 
 2-6 times a week 
 
 About once a week 
 
 A few times a month 
 
 A few times a year 
 
 Rarely or never 
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Thank you for completing this questionnaire.  Please make sure that no questions 
or pages have been skipped.  Please place it in the postage-paid envelope that 
has been provided and seal it.  Please return it to us in the mail.  
 
 
Thank you for your time and cooperation.  You have made an important 
contribution to our study of nutrition and health. 
 
 
Utah State University 
 
 
 
 
